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SUMMARY 
The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are 
produced in different Streptomyces strains and are potent inhibitors of DNA gyrase. 
Cloning and sequencing of the corresponding biosynthetic gene clusters allowed 
detailed investigations of their biosynthetic pathways as well as the generation of 
novel antibiotics by metabolic engineering, chemo-enzymatic synthesis and 
precursor-directed biosynthesis. On the other hand, only limited knowledge is 
available about the regulation of the biosynthesis of the aminocoumarin antibiotics.  
 
The biosynthetic gene cluster of novobiocin, clorobiocin and coumermycin A1 each 
contains two putative regulatory genes with high similarity in between the clusters, i.e. 
novG/cloG/couG and novE/cloE/couE. The function of NovG as a DNA binding 
protein and positive regulator of novobiocin biosynthesis has been established 
previously. In the first part of this thesis, functional proof for the role of novE as a 
positive regulator of novobiocin biosynthesis is provided. Overexpression of novE, 
using a replicative shuttle vector in S. coelicolor strains carrying the intact novobiocin 
cluster has been shown to lead to almost two-fold overproduction of novobiocin, 
suggesting that novobiocin production is limited by the availability of NovE protein. In 
contrast, a novE-defective mutant, generated by an in-frame deletion in this study, 
produced only 0.7 % of the novobiocin amount formed by an S. coelicolor strain 
harboring the intact novobiocin cluster. Novobiocin production in this ΔnovE mutant 
could be restored by introduction of an intact copy of novE, but also by 
overexpression of the regulatory gene novG.  
 
NovE was expressed in E. coli and purified. However, in contrast to NovG, no DNA 
binding properties could be shown for NovE. The following RT-PCR experiments 
showed that at least some novG transcription can occur in the absence of NovE, and 
that novE transcription can occur in the absence of NovG. Correspondingly, 
overexpression of novG under control of its own promoter stimulated novobiocin 
production even in a novE-defective mutant. 
 
Another part of this thesis focuses on the determination of promoter regions within 
the novobiocin biosynthetic gene cluster. For this purpose Ω (omega) interposons, i.e. 
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DNA fragments containing an antibiotic resistance marker flanked by short inverted 
repeats containing termination signals for transcription, were introduced into genes 
downstream of putative promoter regions, i.e. into novE, novF, novG, novH, novO, 
novP, novQ and novS, resulting in termination of mRNA synthesis at the place of 
insertion. Transcription is re-initiated at the next active promoter-sequence 
downstream of the Ω insertion. RT-PCR analysis of the generated mutants showed 
that the novobiocin biosynthetic gene cluster contains, in addition to previously 
identified promoter regions upstream of novE and gyrBR, six further promoter regions 
situated upstream of novF, novG, novH, novO, novP and novQ. 
 
In order to confirm the importance of the promoter regions identified upstream of 
novO, novP and novQ, quantitative RT-PCR experiments were carried out to quantify 
transcription of novH, novP and novQ in the ΩnovH mutant in comparison to 
S.coelicolor strains containing the intact novobiocin cluster. The results of these 
investigations clearly showed that the Ω insertion into novH resulted not only in an 
almost complete loss of novH transcription (< 1 %), but additionally in a very strong 
reduction of transcription of novP and novQ (<3 %). This finding strongly suggests 
that transcription of novO, novP and novQ (and of the genes located downstream 
thereof) is mainly controlled by the novH promoter initiating a large transcript of at 
least 18 kb, i.e. from novH to novW. Furthermore, quantitative RT-PCR was used for 
investigations of the interplay of the two positive regulators novE and novG, as well 
as on their influence on the novobiocin biosynthetic genes. These investigations 
showed that both novE and novG act as transcriptional activators of the genes of 
novobiocin biosynthesis by initiating transcription from the novH-promoter. novE and 
novG act in a cascade-like reaction mechanism, i.e. novE positively regulates 
transcription of novG and NovG regulates transcription of all genes from the novH 
promoter by binding to a well-defined inverted repeat sequence in the intergenic 
region between novG and novH. 
 
Based on the results presented above, the final part of this thesis deals with the 
uncoupling of novobiocin production from its natural regulation cascade by replacing 
the entire novEFG-region, including the promoter region upstream of novH, by a 
strong inducible promoter. For this purpose, the tetracycline-controllable promoter 
830 (tcp830) was used. It has been shown previously, by using luxAB genes 
expressing luciferase as a reporter system, that induction factors of up to 270 could 
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be obtained for tcp830 by induction with anhydrotetracycline. HPLC analysis of 
novobiocin production in the resulting mutants showed that an induced tcp830 
promoter is sufficient to cause transcription of the genes from novH to novW, i.e. of a 
polycistronic mRNA of >18.000 nt, resulting in a two-fold overproduction of 
novobiocin in comparison to strains containing the unmodified novobiocin gene 
cluster. Therefore, regulation of novobiocin production by tcp830 has been confirmed 
as a strategy to uncouple novobiocin production from its natural regulation and 
notably as a further, newly discovered tool to enhance antibiotic production. 
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ZUSAMMENFASSUNG 
Die Aminocoumarin-Antibiotika Novobiocin, Clorobiocin und Coumermycin A1 werden 
von unterschiedlichen Streptomyces-Stämmen gebildet und sind potente 
Gyrasehemmstoffe. Klonierung und Sequenzierung der Biosynthesegencluster dieser 
Antibiotika ermöglichten detaillierte Untersuchungen der Biosynthesewege und die 
Herstellung neuer Antibiotika durch metabolisches Engineering, chemo-
enzymatische Synthese und Vorstufen-gerichtete Biosynthese. Das Wissen über die 
Regulation der Aminocoumarin-Biosynthese ist jedoch begrenzt. 
Die Biosynthese-Gencluster von Novobiocin, Clorobiocin und Coumermycin A1 
enthalten jeweils zwei putative Regulatorgene, novG/cloG/couG und novE/cloE/couE, 
mit starker Ähnlichkeit zwischen diesen Clustern. Die Funktion von NovG als DNA-
bindendes Protein und positiver Regulator in der Novobiocinproduktion wurde bereits 
vor Beginn dieser Arbeit nachgewiesen. Im ersten Teil dieser Arbeit wurde der 
Funktionsnachweis für novE als positiver Regulator der Novobiocinproduktion 
erbracht. Die Überexpression von novE mit Hilfe eines replikativen Shuttle-Vektors in 
Streptomyces coelicolor-Stämmen mit intaktem Novobiocin-Biosynthesegencluster 
führte zu einer nahezu zweifachen Überproduktion von Novobiocin, was darauf 
hindeutet, dass die Novobiocinproduktion durch die Verfügbarkeit von NovE-Protein 
begrenzt wird. Im Gegensatz dazu produzierte die in dieser Arbeit durch „in-
frame“ Deletion hergestellte novE-Defektmutante lediglich 0.7% der 
Novobiocinmenge, die von Streptomyces coelicolor Stämmen mit intaktem 
Novobiocincluster produziert wird. Die Novobiocinproduktion in dieser novE-
Defektmutante konnte nicht nur durch das Einbringen einer intakten Kopie von novE, 
sondern auch durch Überexpression von novG wiederhergestellt werden. 
NovE wurde in Escherichia coli exprimiert und aufgereinigt. Im Gegensatz zu 
Experimenten mit NovG konnte für NovE jedoch keine DNA-bindende Eigenschaft 
nachgewiesen werden. Die folgenden RT-PCR Untersuchungen zeigten, dass 
zumindestens etwas novG-Transkription in Abwesenheit von NovE, und novE-
Transkription in Abwesenheit von NovG stattfindet. In Übereinstimmung damit 
stimulierte die Überexpression von novG unter Kontrolle des eigenen Promotors die 
Novobiocinproduktion auch in der novE-Defektmutante. 
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Der folgende Teil dieser Arbeit zielte auf die Identifizierung der Promotorregionen 
innerhalb des Novobiocin-Biosynthesegenclusters. Zu diesem Zweck wurden Ω- 
(omega) Interposons, das heißt DNA-Fragmente, die einen Antibiotika-
Resistenzmarker beidseitig flankiert durch Sequenzen, die Terminationssignale für 
die Transkription beinhalten, in Gene downstream von putativen Promotorregionen 
eingebracht, das heißt in novE, novF, novG, novH, novO, novP, novQ und novS. 
Dies führte zu einer Termination der mRNA-Synthese. Die Wiederaufnahme der 
Transkription erfolgt von der nächsten aktiven Promotor-Sequenz downstream der Ω-
Insertion. RT-PCR Untersuchungen der generierten Mutanten zeigten, dass im 
Novobiocin-Biosynthesegencluster, zusätzlich zu den bereits identifizierten 
Promotorregionen upstream von novE und gyrBR, sechs weitere Promotorregionen 
enthalten sind, die sich upstream von novF, novG, novH, novO, novP und novQ 
befinden. 
Zur Bestätigung der Rolle der Promotorregionen upstream von novO, novP und novQ, 
wurden quantitative RT-PCR (qRT-PCR) Experimente durchgeführt um die 
Transkription von novH, novP und novQ in der ΩnovH-Mutanten im Vergleich zu 
Streptomyces coelicolor-Stämmen mit intaktem Novobiocincluster zu quantifizieren. 
Die Ergebnisse dieser Untersuchungen zeigten eindeutig, dass die Ω-Insertion in 
novH nicht nur zu einem nahezu vollständigen Ausfall der novH-Transkription (< 1%), 
sondern auch zu einer sehr starken Reduktion der Transkription von novP und novQ 
(<3 %) führt. Diese Ergebnisse machen wahrscheinlich, dass die Transkription von 
novO, novP und novQ sowie der downstream davon liegenden Gene hauptsächlich 
über den novH-Promotor kontrolliert wird, von dem ein mindestens 18 kb großes 
Transkript, das heißt von novH bis novW, gebildet wird. Außerdem wurde mittels 
qRT-PCR das Zusammenspiel der beiden positiven Regulatoren novE und novG, 
sowie deren Einfluss auf die Novobiocin-Biosynthesegene untersucht. In diesen 
Untersuchungen wurden novE und novG als Transkriptionsaktivatoren der 
Novobiocinproduktion bestätigt, welche in einer Regulationskaskade die 
Transkription vom novH-Promotor aus initiieren. Offenbar aktiviert novE die 
Transkription von novG und NovG reguliert über den novH-Promotor die 
Transkription aller Gene durch Bindung an eine definierte Sequenz im intergenischen 
Bereich zwischen novG und novH. 
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Basierend auf den oben präsentierten Ergebnissen beschäftigte sich der letzte Teil 
dieser Arbeit mit der Entkopplung der Novobiocinproduktion von deren natürlichem 
Regelkreis durch Austausch der gesamten novEFG-Region, einschließlich der 
Promotorregion upstream von novH, gegen einen starken Promotor. Hierzu wurde 
der Tetracyclin-induzierbare Promotor 830 (tcp830) verwendet, für den mit den 
Luciferase-kodierenden Genen luxAB als Reporter-System Induktionsfaktoren von 
bis zu 270 beschrieben wurden. Die HPLC-Analyse der Novobiocinproduktion in den 
generierten Mutanten zeigte, dass der tcp830-Promotor erfolgreich eingesetzt 
werden kann, um eine 18 kb umfassende Region von novH bis novW zu 
transkribieren, was zu einer zweifachen Überproduktion von Novobiocin führte. Die 
Regulation der Novobiocinproduktion über tcp830 wurde dadurch nicht nur als eine 
Strategie zur Entkopplung der Novobiocinproduktion von deren natürlichem 
Regulationskreis, sondern auch als ein weiteres, neue entdecktes Werkzeug zur 
Erhöhung der Antibiotikaproduktion bestätigt. 
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I. INTRODUCTION 
I.1. Streptomyces – the largest antibiotic-producing genus 
 
Streptomyces spp. are Gram-positive, filamentous, soil bacteria and ubiquitous in 
nature. They belong to the order Actinomycetales. Remarkable features of 
Streptomyces are the high G+C ratio of their DNA (> 70%) and their large 
chromosome, which consists of 8-10 Mb (Bentley et al., 2002; Bibb et al., 1984; Ikeda 
& Nakagawa, 2003). 
 
Furthermore, they are remarkable in terms of their morphological and metabolic 
differentiation phenomena (Hopwood, 1999). During their complex life cycle, 
Streptomyces differentiate into at least three distinct cell types: substrate hyphae, 
aerial hyphae and spores. Germination of spores is the first step in the development 
of Streptomyces, giving rise to a basal or substrate mycelium, which develops in 
close contact with the nutritive substrate. In response to poorly identified signals 
emanating from the environment and from cellular metabolism, the basal mycelium 
develop aerial hyphae, which ramify and differentiate into spores (Chater, 1998; 
Chater & Horinouchi, 2003). The passage from one mycelial state to the other is 
characterised by a pause in growth and requires the expression of numerous genes 
specific to the aerial mycelium. 
 
This morphological diffentiation is accompanied by metabolic differentiation. 
Generally, Streptomyces spp. produce a large number of very diverse secondary 
metabolites during the later stages of this development. Genes responsible for the 
synthesis of specific secondary metabolism products are clustered on the 
chromosome. These clusters may contain all biosynthetic, regulatory and resistance 
genes required for production of antibiotics. Notably, over two thirds of the clinically 
useful antibiotics of natural origin are produced by Streptomycetes (Kieser et al., 
2000). Till now, over 3000 biological active compounds have been isolated from 
Streptomycetes (including important antibiotics like tetracyclins, vancomycin and 
erythromycin) (Watve et al., 2001). Further bioactive compounds produced by 
streptomycetes are used as antitumoural, antifungal and antiviral agents or as 
herbicides.  
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I.2. Regulation and overproduction of antibiotics production in 
Streptomyces 
 
Antibiotics represent the industrially most important group of secondary metabolites. 
Since two thirds of the clinically useful antibiotics of natural origin are produced by 
Streptomyces (Kieser et al., 2000) it is of major interest to understand how these 
filamentous soil bacteria synthesize antibiotics, to allow manipulation of biosynthetic 
pathways for production of novel compounds with improved properties. Further 
investigations focus on the identification and characterisation of genes involved in the 
regulation of antibiotic biosynthesis, and the use of the resulting knowledge to 
enhance secondary metabolite production. 
 
Biosynthesis of secondary metabolites in Streptomycetes is a complex process 
involving different mechanisms of regulation. Two phylogenetically distant species 
have received especially extensive attention so far: S. coelicolor A3(2) because of its 
early development to a thoroughly studied genetic system which allowed the analysis 
of the interrelation between morphological differentiation and secondary metabolite 
formation; and S. griseus because it provided the first well-studied bacterial example 
of extracellular signalling by a hormone-like lactone, the γ-butyrolactone A-factor 
(Chater & Horinouchi, 2003). In both organisms, antibiotic production is affected by 
pleiotropic regulatory genes that influence the expression of pathway-specific 
regulatory genes which are clustered together with the structural genes of the 
biosynthetic enzymes. 
 
In S. griseus, transcription of streptomycin biosynthetic genes is activated by StrR, a 
pathway-specific regulatory protein which binds to DNA loci containing an inverted 
repeat with the consensus sequence GTTCGActG(N)11CagTcGAAc. These loci are 
situated upstream of the respective promoter regions (Retzlaff & Distler, 1995; 
Tomono et al., 2005). Four StrR binding sites have been identified in the 
streptomycin biosynthetic gene cluster in S. griseus and three in S. glaucescens. 
StrR contains a putative helix-turn-helix (HTH) motif (Retzlaff & Distler, 1995) which 
is typical for a family of bacterial and phage DNA-binding proteins (Pabo & Sauer, 
1992).  
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ActII-ORF4 from S. coelicolor (Arias et al., 1999; Wietzorrek & Bibb, 1997) and DnrI 
from S. peucetius (Sheldon et al., 2002; Wietzorrek & Bibb, 1997) belong to another 
family of regulatory proteins (SARPs). Their predicted secondary structure is an 
OmpR-like DNA-binding domain, and this structure is different from the typical HTH 
motif (Sheldon et al., 2002; Wietzorrek & Bibb, 1997). These proteins act as 
transcriptional activators of target genes by binding to DNA loci that contain direct 
heptameric repeats with the consensus sequence TCGAGCG/C. These loci are 
situated close to the transcriptional start sites (Arias et al., 1999; Wietzorrek & Bibb, 
1997).  
 
Another extensively studied system is the regulation of tylosin biosynthesis in 
Streptomyces fradiae. Tylosin biosynthesis is activated by two positive regulatory 
genes tylS and tylR, which act in a cascade-like reaction mechanism, and their 
overexpression could be used to enhance tylosin production (Bate et al., 2006; Bibb, 
2005). 
 
In other Streptomyces strains further types of pathway-specific regulatory genes have 
been found, like smrR in S. ambofaciens which encoded protein shows no significant 
sequence similarity to any other known regulatory protein; the negative regulator 
mmyR of the methylenomycin cluster in S. coelicolor; and dnrN of the daunorubicin 
cluster in S. peucetius as well as redZ of the undecylprodigiosin cluster in S. 
coelicolor, both representing response regulatory genes of two-component systems. 
However, in some pathways no regulatory gene has been found, i.e. in erythromycin 
pathway (Rawlings, 2001). 
 
Large-scale industrial fermentation requires strains producing high amounts of 
compound to ensure cost effective production, which has been traditionally obtained 
by strain improvements, i.e. expression of the biosynthetic gene cluster in a 
heterologous host or in an industrially optimized strain. Increased secondary 
metabolite production has additionally been obtained by i) metabolic engineering 
redirecting primary metabolic fluxes by introduction of genetic modifications through 
recombinant DNA technology, in a manner to support high secondary metabolite 
productivities (Adrio & Demain, 2006; Nielsen, 1998), ii) engineering antibiotic 
resistance, i.e. actinorhodin and undecylprodigiosin in S. coelicolor and S. lividans by 
introducing point mutations in the rspL gene, encoding the ribosomal protein S12, 
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which confers resistance to streptomycin (Okamoto-Hosoya et al., 2003; Shima et al., 
1996), iii) deregulation of the expression of secondary metabolite pathways, by 
overexpressing pathway-specific positive regulators, i.e. actinorhodin and 
undecylprodigiosin in S. coelicolor by actII-orf4 and redD (Fernández-Moreno et al., 
1991; Narva & Feitelson, 1990), undecylprodigiosin in S.lividans and S.parvulus by 
redD (Malpartida et al., 1990), nikkomycin in S.ansochromogenes by sanG (Liu et al., 
2005) and clavulanic acid in S.clavuligerus by ccaR (Hung et al., 2007; Pérez-Llarena 
et al., 1997) or vice versa, by inactivation of pathway repressors, i.e. chromomycin in 
S.griseus subsp. griseus by inactivation of the transcriptional repressor cmmRII 
(Menendez et al., 2007). Subsequently, the exchange of regulatory genes and 
promoter regions with ermEp*, representing a constitutive promoter, has been 
reported not only to abolish secondary metabolite production from its origin regulation 
circuit, but also to result in enhanced production titers, i.e. the replacement of four 
regulatory genes including the promoter region PJ in the jadomycin gene cluster by 
ermEp* resulted in increased jadomycin B production in Streptomyces venezuelae 
(Zheng et al., 2004). 
 
I.3. Aminocoumarin antibiotics 
 
The closely related aminocoumarin antibiotics novobiocin, clorobiocin and 
coumermycin A1 are produced by different Streptomyces strains. Novobiocin is 
produced by S. spheroides NCIMB 11891 (Berger et al., 1978) and S. niveus (Smith 
et al., 1956). However, Lanoot et al. have proposed that these two strains are 
synonyms of S. caeruleus LMG 19399T (Lanoot et al., 2002). Clorobiocin is produced 
by S. hygroscopicus, S. albocinerescens and S. roseochromogenes var. oscitans 
(Mancy et al., 1974; Ninet et al., 1972). Coumermycin A1 is produced by                    
S. rishiriensis, S. hazeliensis var. hazeliensis, S. spinichromogenes and                    
S. spinicoumarensis (Berger et al., 1978; Kawaguchi et al., 1965). Simocyclinone D8 
(Schimana et al., 2000) and rubradirin (Sohng et al., 1997) are two further 
aminocoumarins found in nature, which are also produced by different Streptomyces 
strains. 
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I.3.1. Chemical structure 
 
Novobiocin, Clorobiocin and Coumermycin A1 contain three structural moieties: a 3-
amino-4,7-dihydroxycoumarin moiety (named Ring B), a deoxysugar moiety (named 
Ring C) and an acyl component (Fig. I.1). Ring B is linked to the acyl component via 
an amide bond, and to Ring C via a glycoside bond. Clorobiocin and novobiocin 
share the same 3-dimethylallyl-4-hydroxybenzoyl moiety (named Ring A) as acyl 
component. Clorobiocin differs from novobiocin at two positions: novobiocin bears a 
carbamoyl group at position 3 of the noviose moiety, while clorobiocin contains a 5-
methylpyrrole-2-carboxylic acid, and clorobiocin, as indicated by its name, carries a 
chlorine atom at position 8 of Ring B, while novobiocin carries a methyl group. 
Coumermycin A1 contains two noviosyl aminocoumarin moieties, and carries a 
different acyl component in comparison to novobiocin and clorobiocin, i.e. a 3-methyl-
pyrrole-2,4-dicarboxylic acid. Coumermycin A1 contains, similar to novobiocin, a 
methyl group at position 8 of Ring B and contains, similar to clorobiocin, the same 5-
methylpyrrole-2-carboxylic acid at position 3 of the noviose moiety (Fig. I.1). 
 
Simocyclinone D8 and rubradirin contain the same aminocoumarin ring as the three 
closely related aminocoumarin antibiotics described above. Furthermore, 
simocyclinone D8 carries a chlorine atom at position 8 of its aminocoumarin ring just 
as clorobiocin. In contrast to novobiocin, clorobiocin and coumermycin A1, 
simocyclinone D8 and rubradirin do not carry a noviose moiety, and their acyl 
components are large and complicated structures (Fig. I.1).  
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Fig. I.1: Structure of the aminocoumarin antibiotics. 
 
I.3.2. Mechanism of action and clinical application 
 
Novobiocin, Clorobiocin and Coumermycin A1 are potent inhibitors of bacterial DNA 
gyrase. The affinity of these drugs to bacterial gyrase is extremely high. The 
equilibrium dissociation constants (KDs) are in the 10 nM range, i.e. two orders of 
magnitude lower in comparison to modern fluoroquinolones. Gyrase belong to type II 
topoisomerase, which are present in all cell types. DNA topoisomerases are essential 
for cell viability and involved in important DNA-processes, i.e. DNA transcription, 
recombination and replication. The presence of DNA-gyrase in all bacteria, but not in 
eukaryotes makes it to a good target for antibacterial agents. With regard to its 
function DNA-Gyrase is responsible for the ATP-dependent introduction of negative 
supercoils into double-stranded DNA. It consists of two subunits: GyrA and GyrB, 
which together build up the active enzyme complex, an A2B2 heterodimer. DNA 
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gyrase has already been isolated from many different bacteria, but so far the one by 
Escherichia coli represents the best characterised. GyrA, a protein of 97 kDa, 
includes an N-terminal domain involved in breakage-resealing reactions and a C-
terminal domain, involved in the DNA-protein interaction. GyrB, a protein of 90 kDa, 
also includes a N-terminal and a C-terminal domain. While the N-terminus (43 kDa) 
catalyses ATP hydrolysis, the C-terminus interacts with GyrA and DNA (Maxwell, 
1997; Maxwell, 1999). 
All three aminocoumarin antibiotics compete with ATP for binding to the B subunit of 
DNA gyrase and inhibit the ATP-dependent DNA supercoiling catalysed by gyrase 
(Maxwell, 1999; Maxwell & Lawson, 2003). In comparison, fluorquinolones inhibit 
gyrase-catalysed supercoiling by disrupting the DNA breakage-reunion reaction on 
GyrA (Jacoby, 2005). X-ray crystallographic studies with the 24 kDa N-terminal 
subdomain of Escherichia coli GyrB showed that both, the aminocoumarin and the 
substituted deoxysugar moieties of these substances are essential for their binding to 
the B-subunit of Gyrase. In these studies the resulting complexes between 
novobiocin (Lewis et al., 1996) and clorobiocin (Tsai et al., 1997) and the protein 
involve hydrophobic interactions and a network of hydrogen bonds. Especially 
hydrogen bonds between Arg136 and the aminocoumarin ring, Asp73 and the 3-acyl 
group on the deoxysugar, and Asn46 and the 2-hydroxyl group on the deoxysugar 
represent key bonds. The drugs do not occupy the same binding-pocket as ATP, but 
the sites for the two ligands overlap: the deoxysugar moiety overlaps the binding-site 
for the adenine ring of ATP. 
Further studies showed that Coumermycin A1 stabilize a dimer form of the 43 kDa N-
terminal fragment of GyrB. This is consistent with the pseudo-dimeric structure of 
coumermycin (Fig. I.1)(Maxwell & Lawson, 2003). 
Topoisomerase IV (topo IV), another bacterial type II topoisomerase has been 
proposed of being a further target of novobiocin (Hardy & Cozzarelli, 2003). 
Topoisomerase IV has a structure similar to bacterial DNA-gyrase: two ParC and two 
ParE subunits building up a C2E2-complex. ParC is responsible for DNA breakage 
and reunion, and ParE contains the ATP binding-site. Mutational experiments in the 
ParE subunit led to the conclusion, that novobiocin inhibits topo IV by the same 
mechanism as DNA gyrase is being inhibited. 
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Aminocoumarin antibiotics show a strong activity against gram-positive bacteria, 
including methicillin- and vancomycin-resistant Staphylococcus strains. Novobiocin 
(Albamycin®, Pharmacia & Upjohn) was licensed as drug in the USA for the treatment 
of human infections with multi-resistant gram-positive bacteria such as 
Staphylococcus aureus and S. epidermidis. Its efficacy has been demonstrated in 
preclinical and clinical trials (Raad et al., 1995; Raad et al., 1998; Walsh et al., 1993). 
However, clinical use of these antibiotics remains restricted, due to some adverse 
reactions (principally urticaria and dermatitis), their poor solubility in water, and their 
low activity against gram-negative bacteria (resulting from poor permeability) 
(Maxwell, 1993). In comparison, clorobiocin and coumermycin have not been used 
clinically. Therefore, the generation of new, structurally modified aminocoumarin 
antibiotics, and of course the test whether they may be able to overcome limitations 
of the known compounds, is still of major interest (Maxwell & Lawson, 2003). 
Further studies showed that aminocoumarins act synergistically with antitumour 
drugs (Lorico et al., 1992; Rappa et al., 1992; Rappa et al., 2000a; Rappa et al., 
2000b). Additionally, interactions with eukaryotic heat shock protein 90 (Hsp90) have 
been described (Burlison & Blagg, 2006; Burlison et al., 2006; Huang & Blagg, 2007). 
 
I.3.3. Structure-activity relationships 
In vitro investigations on the inhibitory activity of aminocoumarin antibiotics and their 
analogues towards E. coli DNA gyrase as well as investigations on their antibacterial 
activity against E. coli cells showed, that the aminocoumarin moiety linked to the 
substituted deoxysugar is important and that lack of the pyrrole or carbamoyl 
substituent resulted in loss of inhibitory activity (Hooper et al., 1982). Furthermore, 
novenamine, i.e. aminocoumarin moiety plus substituted deoxysugar has been 
described to represent the minimal structural entity of novobiocin to obtain interaction 
with DNA gyrase (Reusser & Dolak, 1986). This finding is in accordance with X-ray 
data presented above. The aminocoumarin and deoxysugar moiety alone did not 
show any activity in antibacterial and anti-gyrase activities (Althaus et al., 1988; 
Hooper et al., 1982; Reusser & Dolak, 1986). 
Coumermycin A1 was the most active compound (Hooper et al., 1982). As mentioned 
above, it has been speculated that this effect may be caused by its pseudo-dimeric 
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structure (Maxwell & Lawson, 2003). In comparison to many aryl and alkyl 
substituents tested, the prenylated benzoic acid moiety of novobiocin and clorobiocin, 
i.e. Ring A, was the most effective (Galm et al., 2004; Hooper et al., 1982). Ring A 
was supposed to be unimportant in DNA gyrase interactions and to only facilitate the 
absorption of aminocoumarin compounds (Lewis et al., 1996), which, however, was 
disproved (Freitag et al., 2004; Galm et al., 2004; Lafitte et al., 2002). 
Clorobiocin has been reported to show a higher inhibition of Escherichia coli gyrase 
and bacterial growth than novobiocin (Hooper et al., 1982), and to bind more 
efficiently to isolated gyrase (Lafitte et al., 2002; Lewis et al., 1996; Tsai et al., 1997). 
Most authors have attributed the higher activity of clorobiocin primarily to the pyrrole 
moiety at C-3 of the deoxysugar moiety (Berger et al., 1978; Tsai et al., 1997). 
Interestingly, however, clorobiocin acid, the aglycon of clorobiocin, but not novobiocin 
acid, was found to inhibit both DNA synthesis in vivo and gyrase activity in vitro 
(Althaus et al., 1988; Reusser & Dolak, 1986), suggesting that the chlorine atom 
makes an important contribution to the biological activity of this molecule. 
 
I.3.4. Biosynthetic gene clusters 
 
Structural differences and similarities between novobiocin, clorobiocin and 
coumermycin A1 have been found to be remarkably well reflected by differences and 
similarities in the organization of the respective biosynthetic gene clusters (Pojer et 
al., 2002) (Fig. I.2). 
 
In addition to candidate genes for the biosynthetic reactions, in all three clusters a 
gene for aminocoumarin-resistant gyrB subunit was found downstream of the 
biosynthetic genes for the deoxysugar. The clorobiocin and coumermycin A1 clusters 
contain a second aminocoumarin-resistant gyrB homologue, i.e. parYR (Fig. I.2). 
 
The genes located upstream of nov/clo/couE and downstream of the resistance 
genes are completely different for each cluster (Eustáquio et al., 2003; Schmutz et al., 
2003). These genes may be involved in the primary metabolism, indicating that 
nov/clo/couE and gyrBR/parYR may represent the left and the right borders of these 
clusters respectively (Eustáquio et al., 2003; Schmutz et al., 2003). 
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Fig. I.2: The biosynthetic gene clusters of novobiocin (nov), clorobiocin (clo) and 
coumermycin A1 (cou). Accession numbers: novobiocin cluster AF170880, clorobiocin cluster 
AF329398, coumermycin cluster AF235050 (Li & Heide, 2004). 
 
I.3.4.1. Novobiocin biosynthesis 
The novobiocin biosynthetic gene cluster spans 23.4 kb and comprises 20 coding 
sequences (Li & Heide, 2004; Li et al., 2006; Li & Heide, 2006). The genes 
novHIJKLM are responsible for the synthesis and the linkage of the aminocoumarin 
moiety. novQR are responsible for the generation of the prenylated 4-
hydroxybenzoate moiety, and novSTUVW for the generation of the deoxysugar. novN, 
novO and novP encode enzymes involved in tailoring reactions, i.e. the 
carbamoylation and methylation of the novobiocin skeleton. novF is probably 
responsible for the availability of 4-hydroxyphenylpyruvate, a precursor of both 
aromatic moieties of novobiocin. 
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Fig. I.3: (a) Structure of novobiocin, and function of the gene products of 
novHIJKLMNOPQRSTUVW in novobiocin biosynthesis; 4 HPP, 4-hydroxyphenylpyruvate (Li 
& Heide, 2004). (b) Novobiocin biosynthetic gene cluster. 
 
I.3.5. Resistance genes 
 
Biosynthesis of antibiotics with high biological activity requires mechanisms to protect 
the producer against the inhibitory effect of these compounds. It has been shown that 
the resistance mechanism of the novobiocin producer S. spheroides is based on the 
de novo synthesis of the amincoumarin-resistant GyrB subunit (Thiara & Cundliffe, 
1988). This is obtained by the replacement of the aminocoumarin-sensitive GyrBS 
subunit in the active heterodimer of bacterial DNA-gyrase by GyrBR-protein. 
Therefore, the respective gyrBR-gene was identified in all three clusters, as expected, 
since the producers must obviously protect their gyrases from the inhibitory effect of 
aminocoumarins during antibiotic production. In addition to gyrBR, the coumermycin 
A1 and clorobiocin, but not the novobiocin cluster contain a further gene, i.e. parYR, 
with high sequence similarity to the B-subunit of type II topoisomerases. 
Heterologous expression of gyrBR and parYR in S. lividans TK24 resulted in similar 
levels of resistance against novobiocin and coumermycin A1 (Schmutz et al., 2003). 
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Furthermore, it has been shown that GyrBR leads to resistance against novobiocin 
and coumermycin A1. Heterologous expression and purification of GyrBR and ParYR 
of the coumermycin A1 gene cluster and the corresponding topoisomerase subunits 
GyrA and ParX of Streptomyces coelicolor showed, that ATP-dependent DNA 
supercoiling is catalysed by the in vitro complex of GyrA and GyrBR. For the complex 
of ParX and ParYR an ATP-dependent function of decatenation and relaxation of 
DNA was demonstrated. This function was usually assigned to the topoisomerase IV 
(Schmutz et al., 2004). This finding strongly supports the hypothesis, that topo IV 
may represent a further target for aminocoumarins. 
 
I.3.6. Regulation of aminocoumarin-antibiotic production 
 
Cloning and sequencing of the biosynthetic gene clusters of the aminocoumarin 
antibiotics (Pojer et al., 2002; Steffensky et al., 2000; Wang et al., 2000) allowed 
detailed investigations of the biosynthetic pathways (Li & Heide, 2004) as well as the 
generation of novel antibiotics by metabolic engineering, chemo-enzymatic synthesis 
and precursor-directed biosynthesis (Li & Heide, 2005). 
On the other hand, only limited knowledge is available on how aminocoumarin 
antibiotic production is regulated. The novobiocin biosynthetic gene cluster contains 
two putative regulatory genes, novE and novG. Close orthologues of both genes are 
found in the gene clusters of clorobiocin and coumermycin A1.  
NovG shows 41 % identitiy at the amino acid level to StrR, the pathway-specific 
transcriptional activator of streptomycin biosynthesis in Streptomyces glaucescens 
and S. griseus (Retzlaff & Distler, 1995; Thamm & Distler, 1997; Tomono et al., 2005). 
The predicted amino acid sequence of NovG shows a putative HTH motif in the 
central region of the protein, which is typical for a family of bacterial and phage DNA-
binding proteins (Pabo & Sauer, 1992). This motif is also found in StrR (Retzlaff & 
Distler, 1995; Thamm & Distler, 1997). 
Since the natural novobiocin producer Streptomyces spheroides is difficult to 
manipulate genetically (Hussain & Ritchie, 1991), the biosynthetic gene cluster of 
novobiocin was expressed in S. coelicolor M512 (Eustáquio et al., 2005a) which 
genome sequence (of the wild-type strain S.coelicolorA3(2)) is available (Bentley et 
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al., 2002). In comparison to the natural producer strain the heterologous host showed 
equal novobiocin production titers (Eustáquio et al., 2005a). However, engineering of 
the novobiocin pathway is much easier in the heterologous host than in the wild-type 
strain. 
Inactivation of novG led to a 98 % reduction of the novobiocin productivity of the 
heterologous producer strain (Eustáquio et al., 2005b). Due to the fact that ΔnovG 
strains still produced some novobiocin, an essential catalytic role for novG could be 
ruled out. This finding also indicated a low level expression of the biosynthetic genes 
in absence of NovG. Introduction of novG with its own putative promoter (i.e. 336 bp 
upstream of the start codon of novG) in the expression vector pWHM3 into the 
ΔnovG strain led to restoration of novobiocin production nearly to the same level 
(80%) as observed before novG inactivation, indicating that the observed phenotype 
of ΔnovG strains was indeed caused by the lack of novG (Eustáquio et al., 2005b). 
In comparison, expression of novG from a multicopy plasmid in a S. coelicolor M512 
strain carrying the intact novobiocin cluster resulted in a 2.7-fold overproduction of 
novobiocin, suggesting that novobiocin biosynthesis in the heterologous expression 
host is limited by availability of the activator protein (Eustáquio et al., 2005b). 
As mentioned above, NovG shows sequence similarity to StrR a positive regulator of 
streptomycin biosynthesis. StrR binds to DNA loci containing an inverted repeat with 
the consensus sequence GTTCGActG(N)11CagTcGAAc. These loci are situated 
upstream of the respective promoter regions (Retzlaff & Distler, 1995). 
EMSA (electrophoretic mobility shift assays), in which selected DNA fragments of the 
novobiocin biosynthetic gene cluster were used, demonstrated that His6-tagged 
NovG protein binds specifically to the novG-novH intergenic region (Eustáquio et al., 
2005b). Therefore, it has been speculated that this binding may activate transcription 
of novH, just as described for StrR, which activates transcription of streptomycin 
biosynthetic genes by binding to their promoter regions (Retzlaff & Distler, 1995), 
(Tomono et al., 2005). The putative binding-site of NovG is located directly 
downstream of the translational stop codon of novG, i.e. between -165 and -194 bp 
upstream of the putative translational start codon of novH. Due to the fact that EMSA 
was carried out with nickel affinity purified protein, generated in E. coli, it is very likely 
that NovG binds to DNA with no further macromolecular factor involved. However, 
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the possibility that other proteins may be required for activating the transcription of 
novH may not completely be ruled out. 
As mentioned above, the novobiocin and clorobiocin gene clusters are highly similar 
to each other on amino acid level. It was demonstrated that NovG could also bind to 
a DNA region of the clorobiocin cluster, i.e. the cloG-cloY intergenic region; the 
putative binding-site is located between positions -160 and -189 upstream of the 
putative translational start codon of cloY (Eustáquio et al., 2005b). 
The in silico analysis of the DNA fragments from the novobiocin and clorobiocin 
clusters which bind NovG showed the presence of a conserved 9 bp inverted repeat , 
separated by a less-conserved (two missmatches) 11 bp spacer sequence 
(Eustáquio et al., 2005b). The previously identified StrR binding sites in S. griseus 
and S. glaucescens contain a similar palindromic structure, i.e. conserved inverted 
repeats of 9 bp each, separated by a non-conserved 11 bp spacer (Retzlaff & Distler, 
1995). The same putative NovG binding-site, with exactly the same inverted repeat 
and spacer sequences as found upstream of cloY, is also present in the 
coumermycin A1 cluster, between genes couG and couY. The close similarity of the 
putative NovG/CloG/CouG binding-sites in the novobiocin, clorobiocin and 
coumermycin A1 clusters further indicates a common evolutionary origin for these 
clusters (Eustáquio et al., 2003). 
The consensus sequence GTTCRACTG(N)11CRGTYGAAC or similar motifs were not 
found anywhere else in the gene clusters of novobiocin and clorobiocin, except in the 
mentioned regions upstream of novH and cloY, respectively. In contrast, four StrR 
binding sites have been identified in the streptomycin biosynthetic gene cluster in S. 
griseus and three in the 5´-OH-streptomycin cluster in S. glaucescens (Retzlaff & 
Distler, 1995). 
The predicted gene product of novE comprises 217 amino acids and contains the 
rare TTA-leucine codon (as codon 189) which suggests its dependence on bldA, the 
structural gene for tRNAUUA. This may indicate a regulatory role of NovE in 
novobiocin biosynthesis since most of the known TTA-containing genes specify 
regulatory or resistance proteins associated with biosynthetic gene clusters for 
antibiotics (Leskiw et al., 1991). In addition to that, NovE shows 45 % identity at the 
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amino acid level to LmbU in the lincomycin biosynthetic gene cluster. It has been 
speculated that lmbU may code for a regulatory protein (Peschke et al., 1995). 
Orthologues of novE and lmbU include cloE and couE from the clorobiocin and 
coumermycin gene clusters, rubC4 from the gene cluster of the aminocoumarin 
antibiotic rubradirin (GenBank AJ871581) and five further genes deposited in the 
database. All of these genes have been found in actinobacteria. However, their 
function is yet unknown. 
 
Heterologous expression experiments showed that the expression of the complete 
novobiocin cluster, i.e. nov-BG1, including several kb of DNA upstream of the start 
codon of novE (Fig. I.4), in the heterologous host Streptomyces coelicolor M512 
resulted in a high production of novobiocin. In contrast, the expression of a similar 
construct, i.e. novAE4, including only 180 bp upstream of the novE start codon (Fig. 
I.4) had given only 5 % of the production achieved with nov-BG1 (Eustáquio et al., 
2005a). Subsequently, the expression of a construct which contained 484 bp 
upstream of the novE start codon (Fig. I.4), i.e. nov-AE12, resulted in 12 times higher 
production levels in comparison with nov-AE4 (Dangel et al., 2008). The additional 
DNA region contained in nov-AE12 but not in nov-AE4 comprises only the 3´-end of 
the structural gene novD, without a start codon. Therefore, this effect cannot be 
attributed to the expression of a functional NovD protein. This finding may represent 
an indication that the promoter region of novE extends more than 180 bp upstream of 
the novE start codon, and that expression of novE is important for novobiocin 
biosynthesis.  
 
 
Fig. I.4: Schematic comparison of the inserts of cosmids nov-BG1, nov-AE12 and nov-AE4. 
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In the course of investigations on the genes at the borders of the novobiocin, 
clorobiocin and coumermycin gene clusters, a replacement of novE with an 
apramycin resistance gene has been carried out in the novobiocin producer 
Streptomyces spheroides (syn. Streptomyces caeruleus) (Eustáquio et al., 2003). 
This resulted in a reduction of the novobiocin production by 96 % but not in a 
complete abolishment. This result indicated that novE may act as a positive regulator 
of novobiocin biosynthesis. However, downstream effects of the introduced 
apramycin resistance cassette can not be excluded. 
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I.4. Aims of this study 
 
The first aim of this study was to supply functional evidence for the regulatory role of 
novE in novobiocin biosynthesis. For this reason the following experiments have 
been carried out: 
- Inactivation of novE in cosmid nov-BG1 and heterologous expression of the 
resulting ΔnovE-cosmid in Streptomyces coelicolor M512. 
- Complementation of the ΔnovE-mutation by introducing an intact copy of novE 
on a multicopy number plasmid (pWHM3-based) into Streptomyces coelicolor 
M512 (ΔnovE). 
- Overexpression of an intact copy of novE on a multicopy number plasmid 
(pWHM3-based) in Streptomyces coelicolor M512 (nov-BG1). 
- Introduction of the positive regulator novG under control of the constitutive 
ermE* promoter (pUWL-based) into Streptomyces coelicolor M512 (ΔnovE). 
- HPLC analysis of secondary metabolite production in the generated mutants. 
 
The second aim of this study was to show whether novE and novG act in a cascade-
like or a parallel mechanism. Therefore, the following experiments have been carried 
out: 
- Introduction of an intact copy of novG under control of its own putative 
promoter on a multicopy number plasmid (pWHM3-based) into Streptomyces 
coelicolor M512 (ΔnovE). 
- Introduction of an intact copy of novE under control of its own putative 
promoter on a multicopy number plasmid (pWHM3-based) into Streptomyces 
coelicolor M512 (ΔnovG). 
- Establishment of methods for RNA isolation from Streptomyces and for RT-
PCR. 
- RT-PCR analysis for investigations on novG transcription in Streptomyces 
coelicolor M512 (ΔnovE) and novE transcription in Streptomyces coelicolor 
M512 (ΔnovG). 
 
Further aims were the determination of promoter regions and investigations on the 
transcriptional regulation of the novobiocin biosynthetic gene cluster. Investigations 
on the determination of promoter regions within the novobiocin biosynthetic gene 
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cluster were carried out in cooperation with Johannes Härle as diploma student and 
included the following experiments: 
- Introduction of Ω (omega) interposons downstream of putative promoter 
regions into cosmid nov-BG1, resulting in interruption of transcription up to the 
next active promoter region. 
- Heterologous expression of the modified constructs in Streptomyces coelicolor 
M512. 
- RT-PCR analysis of the generated mutants. 
Investigations on the transcriptional regulation required the establishment of 
quantitative RT-PCR. Quantitative RT-PCR experiments were carried out for 
contribution of the promoter regions within the region from novH to novW and for 
investigations on the interplay of novE and novG as well as on the influence of novE- 
and novG-inactivation on the transcription of novobiocin biosynthetic genes and the 
resistance gene gyrBR. 
 
Subsequently, the final aim of this study was the generation of Streptomyces 
coelicolor M512 strains with improved novobiocin production, independent from its 
origin regulation cascade. Therefore the following experiments were carried out: 
- Generation of S. coelicolor M512 (ΔnovEΔnovG). 
- Introduction of tetracycline-controllable-promoters (tcp830) into cosmid nov-
BG1 in exchange for the entire novEFG-region and/or for the intergenic region 
between novP and novQ. 
- Heterologous expression of the modified cosmids in Streptomyces coelicolor 
M512. 
- HPLC analysis of secondary metabolite production, with and without induction  
 by anhydrotetracycline. 
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II. MATERIALS AND METHODS 
II.1. Chemicals 
Chemicals and components of the media used in this thesis are listed in Table II.1.  
TABLE II.1: Chemicals and media components 
Supplier Chemical / Media component 
Amersham Biosciences, Freiburg, 
Germany 
Agarose 
Bacto-Difco, Heidelberg, Germany Agar 
Casaminoacids 
Malt extract 
Peptone  
Tryptic soy broth 
Tryptone  
Yeast extract 
Calbiochem-Novabiochem, Bad 
Soden, Germany 
L-Proline 
Thiostrepton 
Fluka, Ulm, Germany Apramycin 
Novobiocin 
FMC BioProducts, Rockland, USA NuSieve® GTG® Agarose 
Merck, Darmstadt, Germany Chloramphenicol 
EDTA  
Ethanol 
Glucose   
Meat extract 
Methanol  
Roth, Karlsruhe, Germany Anhydro-tetracycline (aTc) 
5-Bromo-4-chlor-3-indolyl-β-D-
galactopyranoside (X-Gal) 
Carbenicillin 
Glacial acetic acid 
Glass beads 
Glycine 
Isopropanol 
Isopropyl-β-thiogalactoside (IPTG) 
Maleic acid 
Na-salicylat 
Phenol/Chloroform/Isoamylalkohol(25:24:1) 
Phenol (pH 8.0) 
Polyethyleneglycol (PEG) 1000 
Sodium dodecyl sulphate (SDS) 
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Tris-(hydroxymethyl)-aminomethane-maleate 
(Tris-maleate) 
N-Tris-(Hydroxymethyl)-methyl-2-aminoethane 
sulfonic acid (TES) 
Serva, Heidelberg, Germany N-Lauroylsarcosine (Na-Salt, 35%) 
Sigma-Aldrich, Deisenhofen, 
Germany 
Bromophenol blue  
Dimethyl formamide (DMF) 
Dimethyl sulfoxide (DMSO) 
Ethyleneglycol 
Kanamycin  
Polyoxyethylenesorbitan monolaurate (Tween 
20) 
Tetracycline 
Tris base 
Südzucker, Mannheim, Germany Sucrose  
 
II.2. Materials for Chromatography 
The liquid chromatography media were obtained as commercial columns. The 
storage of the columns was carried out according to the manufacturers’ instructions. 
TABLE II.2: Liquid chromatography media 
Supplier Medium 
C+S Chromatographie Service, 
Düren, Germany 
Multosphere® RP 18-5 (commercial colum, 5 
µm, 150×4,6 mm 
II.3. Enzymes and kits 
TABLE II.3: Enzymes and kits 
Supplier Enzymes and kits 
Amersham Biosciences, Freiburg, 
Germany 
Restriction endonucleases 
T4 DNA Ligase 
Fermentas Deoxyribonuclease I (1 U/µl) 
10 x buffer with MgCl2 (100 mM Tris-HCl 
(pH 7.5 at 25 °C), 25 mM MgCl2, 1mM CaCl2) 
Random hexamer primers (0.2 µg/ml) 
Revert-Aid™M-MuLV Reverse Transcriptase 
(200 U/µl) 
5 x reaction buffer (250 mM Tris-HCl (pH: 8.3 
at 25 °C), 250 mM KCl, 20 mM MgCl2, 50 mM 
DTT) 
RiboLock™ Ribonuclease Inhibitor (20 U/µl) 
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10 mM dNTP-mix (10 mM each) 
1 kb DNA Ladder 
Fluka, Ulm, Germany Lysozyme (47 000 U/mg) 
Lysozyme (85 400 U/mg) 
Macherey-Nagel, Düren, Germany Nucleobond® AX100 
NucleoSpin® Extract 2 in 1 
Nucleo-spin® RNA Clean-up 
New England Biolabs, Schwalbach, 
Germany 
Restriction endonucleases 
T4 DNA Ligase 
100 bp DNA Ladder 
Plant Bioscience Limited, Norwich, 
UK 
REDIRECT© technology: PCR-targeting 
system in Streptomyces coelicolor 
Promega, Madison, WI, USA pGEM-T Easy® Vector System 1 
Taq DNA polymerase 
Pfu DNA polymerase 
Qiagen, Hilden, Germany RNase A (100g/ml) 
Roche, Mannheim, Germany DNA Molecular Weight Marker VII, DIG-
Labelled 
Expand High Fidelity PCR System  
LightCycler® RNA ampflication Kit SYBR 
Green I 
Strategene, Taufkirchen, Germany Restriction endonucleases 
II.4. Media, buffers and solutions 
II.4.1. Media for bacterial cultivation 
The media used in this study were as follows. Unless otherwise stated, the media 
were prepared with distilled water and autoclaved for 20 min at 121 °C (15 psi). To 
obtain solid media, 2% (w/v) agar was added before autoclaving. If necessary, sterile 
supplementary components like antibiotics and other heat-labile substances were 
added in the sterile media at time of use. The media were stored at room 
temperature or at 4 °C. 
II.4.1.1. Cultivation of E. coli 
 
LB (Luria-Bertani) Medium (Sambrook & Russell, 2001) 
NaCl                                10.0 g 
Tryptone                          10.0 g 
Yeast extract                     5.0 g 
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Dissolve the ingredients in about 900 ml water, adjust the pH to 7.0, and 
adjust the volume to 1 litre with water. Sterilize by autoclaving. 
 
SOB Medium 
Tryptone                          20.0 g 
Yeast extract                     5.0 g 
NaCl                                  0.5 g 
 
Dissolve the ingredients in about 900 ml water, adjust the pH to 7.0, and 
adjust the volume to 1 litre with water. Sterilize by autoclaving. Add 10 ml 
of a sterile solution of 1 M MgCl2. 
 
II.4.1.2. Cultivation of Streptomyces 
 
YMG (Yeast-Malt-Glucose) Medium 
Yeast extract                     4.0 g 
Malt extract                     10.0 g 
Glucose                             4.0 g 
 
Dissolve the ingredients in about 900 ml water, adjust the pH to 7.3, and 
add water to make up to 1 litre. Sterilize by autoclaving. 
 
TSB (Tryptone Soya Broth) Medium (Kieser et al., 2000) 
Tryptone Soya Broth  30.0 g 
Dissolve the ingredient in up to 1 litre water, and sterilize by autoclaving. 
 
MS (Mannitol Soya flour) Agar (Kieser et al., 2000) 
Mannitol    20.0 g 
Soya flour   20.0 g 
Agar    20.0 g 
 
Dissolve the mannitol in up to 1 litre tap water and pour 100 ml into 300 ml 
Erlenmeyer flasks each containing 2 g agar and 2 g soya flour. Sterilize by 
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autoclaving twice (115 ºC, 15 min) with gentle shaking between the two 
runs.  
 
DNA (Difco Nutrient Agar) (Kieser et al., 2000) 
Difco Nutrient Agar  4.6 g 
 
Place the ingredient into 300 ml Erlenmeyer flasks and add 200 ml water. 
Sterilize by autoclaving. 
 
MM Medium (Kieser et al., 2000) 
L-asparagine      0.5 g 
K2HPO4      0.5 g 
MgSO4  7H2O      0.2 g 
FeSO4  7H2O   0.01 g 
Mannitol         5 g 
Agar        10 g 
Distilled water      ad 1000ml 
 
Dissolve the ingredients, except agar, in the distilled water, adjust to pH 
7.0-7.2 and dispense 200 ml into 300 ml Erlenmeyer flasks each containing 
2 g agar. Close the flasks and sterilize by autoclaving.  
 
II.4.1.3. Novobiocin production medium 
CDM medium (Kominek, 1972) 
tri-sodium citrate  2H20  6.0 g 
L-proline                               6.0 g 
K2HPO4  3H2O    2.0 g 
(NH4)2SO4    1.5 g 
NaCl     5.0 g 
MgSO4  7H2O            2.05 g 
CaCl2  2H2O    0.4 g 
ZnSO4  7H2O    0.1 g 
Glucose (30% (w/v))   100 ml 
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Dissolve the ingredients till NaCl in water, adjust the pH to 7.2, dissolve the 
remaining ingredients except the glucose solution, and add water to make 
up to 900 ml. Sterilize by autoclaving. Add the sterile glucose solution. 
 
II.4.1.4. Protoplast transformation of Streptomyces 
Trace elements solution 
ZnCl2    40 mg 
FeCl3  6H2O           200 mg 
CuCl2  2H2O   10 mg 
MnCl2  4H2O   10 mg 
Na2B4O6  10H2O  10 mg 
(NH4)6Mo7O24  4H2O  10 mg 
 
Dissolve in 1 litre distilled water and autoclave. 
 
R5 Medium (Kieser et al., 2000) 
Sucrose            103.0 g 
K2SO4    0.25 g 
MgCl2  6H2O           10.12 g 
Glucose    10.0 g 
Difco Casaminoacids    0.1 g 
Trace elements solution 2.0 ml 
DifcoYeast extract    5.0 g 
TES buffer   5.73 g 
Agar (plates)   23.0 g 
 
Dissolve in water to a final volume of 1 litre and sterilize by autoclaving. To 
prepare soft agar, 6 g Agar instead of 23 g, were added. 
After autoclaving, add the following sterile solutions: 
KH2PO4 (0.5%)   10 ml 
CaCl2  2H2O (5 M)    4 ml 
L-Proline (20% (w/v))  15 ml 
NaOH (1M)     7 ml 
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II.4.2. Antibiotic solutions 
Antibiotics were dissolved in appropriate solvents as stock solutions and kept at         
-20 °C. The aqueous solutions were sterilized by passing through a 0.22 µm filter. 
The solutions in ethanol and DMSO were autosterile. For antibiotic selection, the 
required antibiotics were added to the cooled media (room temperature to 60 °C) in 
appropriate concentration. 
TABLE II.4: Solutions of antibiotics 
Concentration in 
Antibiotic 
stock solution (mg/ml) media (µg/ml) 
Solvent 
Apramycin 50 15-50a H2O 
Carbenicillin 50-100 50-100 H2O 
Chloramphenicol 25-50 25-50 ethanol 
Kanamycin 50 15-50a H2O 
Anhydrotetracycline 50 1b H2O 
Tetracycline 12 12 ethanol 
Thiostrepton 50 15-50a DMSO 
a15 µg/ml in liquid and 50 µg/ml in solid media for selection of Streptomyces 
strains; otherwise, 50 µg/ml. 
b anhydrotetracycline was used for induction of tcp830. 
 
II.4.3. Buffers and solutions 
Unless otherwise stated, the buffers and solutions were prepared with distilled water, 
autoclaved and stored at room temperature. 
 
II.4.3.1. Buffers and Solutions for DNA isolation 
TABLE II.5: Buffers and solutions for plasmid and cosmid isolation from E.coli 
Buffer Components Final concentration Preparation 
Solution 
MP1 
Tris-HCl 
EDTA 
RNase A 
50 mM 
10 mM 
100 µg/ml 
Adjust the pH to 8.0. Add 
RNase A just before use. 
Solution 
MP2 
NaOH 
SDS 
0.2 M 
1% (w/v) 
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Solution 
MP3 
KAc  3H2O 3 M Adjust the pH to 4.8. Store at 4 
°C.  
 
TABLE II.6: Buffers and solutions for plasmid isolation from Streptomyces  
Buffer Components Final concentration Preparation 
Solution 
MP1GL 
Glucose 
Tris-HCl 
EDTA 
RNase A 
Lysozyme 
50 mM 
25 mM 
10 mM 
100 µg/ml 
2-4 mg/ml 
Adjust the pH to 8.0. Add 
RNase A and lysozyme just 
before use. 
Solution 
MP2 
NaOH 
SDS 
0.2 M 
1% (w/v) 
 
Solution 
MP3 
KAc  3H2O 5 M Adjust the pH to 4.8. Store at  
4 °C. 
 
TABLE II.7: Buffers for isolation of genomic DNA from Streptomyces 
Buffer Components Final 
concentration 
Preparation 
TSE buffer Sucrose 
Tris-HCl 
EDTA 
RNase A 
Lysozyme 
10.3% 
25 mM 
25 mM 
100 µg/ml 
3 mg/ml 
Adjust the pH to 8.0. Add 
RNase A and lysozyme just 
before use. 
2Kirby mix SDS 
Sodium 4-
aminosalicilate 
2 M Tris-HCl 
pH 8 
equilibrated 
phenol pH 8.0 
2 g 
12 g 
 
5 ml 
 
 
6 ml 
Dissolve the SDS and the 
sodium 4-aminosalicilate in up 
to 89 ml distilled water, add 
the Tris-HCl buffer and the 
phenol. Do not autoclave. 
Store protected from light at  
4 ºC. 
TE buffer Tris-HCl 
EDTA 
10 mM 
1 mM 
Adjust the pH to 7.5.  
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II.4.3.2. Buffers for DNA gel electrophoresis 
TABLE II.8: Buffers for DNA gel electrophoresis 
Buffer/solution Components Final concentration
Preparation 
50×TAE Tris base 
EDTA 
Glacial acetic acid  
2 M 
0.05 M 
57.1 ml/l 
Adjust the pH to 8.0 
with glacial acetic 
acid. 
Load buffer Glycerol  
Bromophenol blue 
30% (w/v) 
0.25% (w/v) 
Store at 4 °C 
Ethidium bromide 
solution for staining 
the agarose gel 
Ethidium bromide 1 µg/ml  
 
 
II.4.3.3. Buffers and solutions for Southern blot analysis 
TABLE II.9: Buffers and solutions for Southern blot analysis 
Buffer/solution Components Final 
concentration
Preparation 
Denaturing 
solution 
NaOH 
NaCl 
0.5 M 
1.5 M 
 
Neutralizing 
buffer 
Tris-HCl 
NaCl 
0.5 M 
3 M 
Adjust the pH to 7.5. 
20×SSC buffer Trisodium citrate 
NaCl 
0.3 M 
3 M 
Adjust the pH to 7.0 
Pre-hybridizing 
solution 
Creamed milk powder 
SDS (10% (w/v) in H2O)  
N-lauroylsarcosine (35% 
(w/v) in H2O) 
3% 
0.02% 
0.1% 
Add to 5×SSC buffer 
before use.  
Hybridizing 
solution 
Creamed milk powder 
SDS (10% (w/v) in H2O)  
N-lauroylsarcosine (35% 
(w/v) in H2O) 
1.5% 
0.02% 
0.1% 
Add to 5×SSC buffer 
before use. Add 
appropriate probe 
(5-25 ng/ml) 
2×Washing 
buffer 
SDS (10% (w/v) in H2O)  
 
0.1% Add to 2×SSC buffer 
before use.  
0.5×Washing 
buffer 
SDS (10% (w/v) in H2O)  
 
0.1% Add to 0.5×SSC 
buffer before use.  
Maleic acid 
buffer 
Maleic acid  
NaCl 
0.1 M 
0.15 M 
Adjust the pH to 7.5  
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Tween® wash 
buffer 
Tween® 20 0.3% Add to the maleic 
acid buffer before 
use. 
Blocking solution Creamed milk powder 3% Add to the maleic 
acid buffer just 
before use 
Detection buffer Tris-HCl 
NaCl 
0.1 M 
0.1 M 
Adjust the pH to 9.5 
Antibody solution Blocking solution  
Anti-DIG-AP-conjugate 
40 ml 
4 µl 
Mix just before use. 
Stripping solution 
for blot 
NaOH 
SDS (10% (w/v) in H2O) 
0.2 M 
0.1% 
 
 
II.4.3.4. Solutions for blue/white selection of E. coli 
The storage was carried out at -20°C. 
TABLE II.10: Stock solutions for blue/white selection. 
Solution Composition Per plate 
IPTG 80 mg/ml in distilled water, sterilize by filtering  15 µl 
X-Gal 20 mg/ml in DMF, autosterile 60 µl 
 
II.4.3.5. Buffers for preparation of protoplasts and transformation of 
Streptomyces 
The following sterile solutions were prepared separately. To obtain P-buffer and T-
buffer, they were mixed according to the description and stored at -20°C. 
TABLE II.11: Buffers for preparation of protoplasts and transformation of 
Streptomyces 
Buffer Components Amount (ml) 
P(protoplast)-buffer 
(Kieser et al., 2000) 
Sucrose (12% (w/v) in H2O) 
MgCl2  6H2O (1M) 
K2SO4   (140 mM) 
Trace elements solution  
KH2PO4 (40 mM) 
CaCl2  2H2O (250 mM) 
TES (0.25M, pH 7.2) 
85.5 
1.0 
1.0 
0.2 
1.0 
1.0 
10.0 
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T(transformation)-
buffer 
(Kieser et al., 2000) 
Sucrose (25% (w/v) in H2O) 
Trace elements solution 
K2SO4 (140 mM) 
KH2PO4 (40 mM) 
MgCl2  6H2O (1 M) 
CaCl2  2H2O (5 M) 
Tris-maleate (0.5 M, pH 8.0) 
PEG 1000 (50% (w/v) in H2O); 
 
1.0 
0.03 
0.1 
0.1 
0.1 
1.0 
1.0 
                 5.0 
adjust the volume with 
distilled water to 10 ml. 
 
II.4.3.6. Solution for isolation of RNA from Streptomyces 
TABLE II.12: Solution for isolation of RNA from Streptomyces 
Solution Components Final concentration Preparation 
Modified Kirby 
mix 
N-lauroylsarcosine 
Sodium-salicylate 
2 M Tris-HCl pH 8.0 
Phenol pH 8.0 
1 % (w/v) 
6 % (w/v) 
20 mM 
6 % (v/v) 
Dissolve N-
lauroylsarcosine, 
sodium-
salicylate in 
distilled water, 
add the Tris-HCl 
buffer and the 
phenol and add 
distilled water up 
to 100 ml. Do 
not autoclave. 
Store protected 
from light at 4°C.
 
 
 
II.5. Plasmids, bacterial strains, primers and probes 
II.5.1. Vectors, cosmids and plasmids 
TABLE II.13: Vectors, cosmids and plasmids 
Name Description Source or reference 
Vector 
pGEM-T Linearized vector with T-overhang for direct 
cloning of PCR fragments with A-overhang, 
lacZ, ori, f1-origin, AmpR 
Promega 
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pUWL 201 E. coli - Streptomyces shuttle vector, ermE* 
promoter, AmpR, ThioR 
(Doumith et al., 
2000) 
pWHM3 E. coli - Streptomyces shuttle vector, lacZ, 
AmpR, ThioR 
(Vara et al., 
1989) 
Cosmid 
nov-BG1 From cosmid 10-9C, bla gene replaced by 
cassette from pIJ787 (oriT, tet, attP, int C31), 
KanR. 
Bertolt Gust 
(Eustáquio et 
al., 2004) 
nov-AE10 nov-BG1 (ΔnovG), KanR (Eustáquio et 
al., 2005b) 
nov-JH4 nov-BG1 (ΩnovH); KanR ApraR Johannes 
Härle´s Thesis
Plasmid 
pIJ787 SuperCos1-derivative, bla gene replaced by a 
cassette containing oriT, tet, attP, int C31, 
KanR 
Bertolt Gust  
(Eustáquio et 
al., 2004) 
pUG019 pBlueskript SK(-)-derivative containing an 
apramycin resistance (aac(3)IV) cassette 
flanked by XbaI and SpeI restriction sites, AmpR 
Ute Galm 
(Eustáquio et 
al., 2004) 
pMS80 Plasmid containing the tetracycline-controllable 
promoter 830 (tcp830); ApraR 
(Rodriguez-
Garcia et al., 
2005) 
pAE8 1.43 kb BamHI-EcoRI fragment of pMS33 
(novG, position 6 393 – 7 821, AF 170880) in 
the same sites of pWHM3, containing 336 bp 
before the putative start codon of novG; AmpR, 
ThioR 
(Eustáquio et 
al., 2005b) 
pAE12 1.35 kb PstI-SphI fragment of pAE11, cloned 
into the same sites of pWHM3 (same orientation 
as lacZ), containing novG and 336 bp upstream 
of its start codon (position 6383 - 7687 in 
AF170880); AmpR ThioR 
Alessandra 
Eustáquio´s 
studies 
 
TABLE II.14: Plasmids and cosmids produced in this study 
Name Description 
Plasmid 
pVD1 1 kb BamHI/HindIII fragment of pAE-G4 into the same sites of 
pUWL201, cointaining novG (position 6720 - 7704 in GenBank entry 
AF170880); AmpR, ThioR 
pVD4 1.314 kb PstI/SphI fragment of pVD7 into the same sites of pWHM3, 
containing novE and 599 bp upstream of its start codon; AmpR, ThioR 
 II. MATERIALS AND METHODS 37 
pVD7 PCR fragment comprising novE (position 4209 – 5461 in AF170880) 
in pGEM-T; AmpR 
pVD10 1.31 kb HindIII-SphI fragment of PCR product comprising novE
(position 4209-5461 in AF170880) into the same sites of pAE12 
Cosmid 
nov-VD1 From nov-BG1, novE replaced by the apramycin resistance cassette 
from pUG019, KanR, ApraR 
nov-VD2 From nov-VD1, apramycin resistance cassette excised by expression 
of FLP-recombinase; ΔnovE cosmid (Fig. III.1), KanR 
nov-VD3 From nov-AE10, novE replaced by the apramycin resistance cassette 
from pUG019, KanR, ApraR 
nov-VD4 From nov-VD3, apramycin resistance cassette excised by expression 
of FLP-recombinase; ΔnovEΔnovG cosmid (Fig. III.8), KanR 
nov-VD6 From nov-BG1, region novD stop codon to novH start codon replaced 
by apra-tcp830 from pMS80 (Fig. III.8); KanR, ApraR 
nov-VD7 From nov-VD6, apramycin resistance cassette excised by expression 
of FLP-recombinase (Fig. III.8); KanR 
nov-VD8 From nov-BG1, intergenic region novP_novQ replaced by apra-
tcp830 from pMS80 (Fig. III.8); KanR, ApraR 
nov-VD9 From nov-VD7, intergenic region novP_novQ replaced by apra-
tcp830 from pMS80 (Fig. III.8); KanR, ApraR 
 
 
 
II.5.2. PCR primers used for construction of plasmids 
TABLE II.15: Primers used for construction of plasmids 
Name Sequence (5’-3’)a Restriction site 
Positions 
(Acession 
number) 
Plasmid
PnovE_f CCGACGCCTTCACCACCACG --- 4209 - 4228 (AF170880) 
PnovE_r GTCAAACGGCCCCGTCCACG --- 5443 - 5462 (AF170880) 
pVD7 
P10_novE_f AAAAAAAAGCTTCCGACGCCTTCACCACCACG HindIII 
4209 - 4228 
(AF170880) 
P10_novE_r AAAAAAGCATGCGTCAAACGG
CCCCGTCCACG 
SphI 5443 - 5462  (AF170880) 
pVD10 
aUnderlines letters represent restriction sites HindIII and SphI. 
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II.5.3. Primers used for RT-PCR experiments 
TABLE II.16: Primers used for RT-PCR experiments 
 
Name Sequence (5´-3´) Position Target 
gene 
P_hrdB_RT_f TCGGCCAGCACATCCCGTAC 6367668 - 6367687 
P_hrdB_RT_r TCGGTACCCTCGGGCTCCTC 6368203 - 6368222 
hrdB 
P_novE_RT_f GACGCGACCCCCGTTGACAG 4880 - 4889 
P_novE_RT_r GCCTCCCTCCACCGTTCGAG 5378 - 5397 
novE 
P_novG_RT_f CCAACAGCGGCGATGAGGAG 6734 - 6753 
P_novG_RT_r CGGTGGACGACGACCTCAGC 7173 - 7192 
novG 
The GenBank accession number for  the sequence reported is AF170880 
(novobiocin cluster) and SCO5820 (hrdB).  
 
II.5.4. Primers used for qRT-PCR experiments 
Table II.17: Primers used for qRT-PCR experiments 
 
Name Sequence (5´-3´) Position  Target
gene 
P_hrdB_qRT_f TGACGCTGATGGTCAGTGC 6367864 - 6367882 
P_hrdB_qRT_r GTCGCCTTCCTGCTGGTC 6367969 - 6367987 
hrdB 
P_novE_qRT_f GATCCCGCGGGACCTCTC 4963 - 4980 
P_novE_qRT_r CCAGCCAGTCGCCGATCC 5043 - 5060 
novE 
P_novF_qRT_f GGAATGATCGGCAGATCCAT 5563 - 5582 
P_novF_qRT_r CAGTGCGACGGGACTGGT 5628 - 5646 
novF 
P_novG_qRT_f GTCGTGCACCGTGGGACC 6901 – 6918 
P_novG_qRT_r ACACATCGGCCGGGGAGC 7001 - 7018 
novG 
P_novH_qRT_f CGAAACGGCTGGCACGAC 8048 – 8065 
P_novH_qRT_r GCCACGGCAAGCACGCTG 8138 - 8156 
novH 
P_novO_qRT_f CGTCCTCAACTGCTCCTTCA 17908 – 17927 
P_novO_qRT_r GCGTAATGGTGAGCCAGCG 18021 - 18039 
novO 
P_novP_qRT_f GCCGGGACGGTGTACGAG 18301 - 18318 
P_novP_qRT_r TGCGTTCGCGGGCCAGTC 18391 - 18408 
novP 
P_novQ_qRT_f GTGTGCTTCTACGCCCTGA 19728 – 19746 novQ 
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P_novQ_qRT_r CCGAACGACCAGCCGATG 19837 - 19855  
P_gyrBR_qRT_f CTCAGAGAACCGCAGTTCG 39918 - 39936 
P_gyrBR_qRT_r ACCAGTCGGTCAGATGCTC 40002 - 40020 
gyrBR 
The GenBank accession number for  the sequence reported is AF170880 
(novobiocin cluster), SCO5820 (hrdB) and AF205854 (gyrBR) 
 
 
II.5.5. Bacterial strains 
TABLE II.18: Bacterial strains of E. coli and Streptomyces 
Strain Relevant characteristics Source or reference 
E. coli XL1Blue 
MRF’ 
General cloning host (recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
laclqZDM15 Tn10 (TetR)]), TetR 
Stratagene 
E. coli ET 12567 Strain triply defective in DNA methylation 
(dam- dcm- hsdM-), TetR, CmR 
(MacNeil et al., 
1992) 
S. coelicolor M512 redD actII-ORF4 SCP1- SCP2- (no 
production of actinorhodin, 
undecylprodigiosin, and methylenomycin) 
(Floriano & Bibb, 
1996) 
S. coelicolor M512 
(nov-BG1) 
S. coelicolor M512 containing the 
novobiocin cluster and flanking DNA 
regions, KanR 
(Eustáquio et al., 
2004) 
S. coelicolor M512 
(nov-BG1)/pWHM3 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-BG1)/pVD4 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-AE10) 
S. coelicolor M512 containing a novG-
defective novobiocin cluster, KanR 
(Eustáquio et al., 
2005b) 
S. coelicolor M512 
(nov-AE10)/pWHM3 
KanR, ThioR (Eustáquio et al., 
2005b) 
S. coelicolor M512 
(nov-AE10)/pAE8 
KanR, ThioR (Eustáquio et al., 
2005b) 
S. coelicolor M512 
(nov-AE10)/pVD4 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-VD2) 
S. coelicolor M512 containing a novE-
defective novobiocin cluster, KanR 
This thesis 
S. coelicolor M512 
(nov-VD2)/pWHM3 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-VD2)/pVD4 
KanR, ThioR This thesis 
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S. coelicolor M512 
(nov-VD2)/pVD1 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-VD2)/pAE8 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-VD4) 
S. coelicolor M512 containing a 
novE,novG-defective novobiocin cluster, 
KanR 
This thesis 
S. coelicolor M12 
(nov-VD4)/pWHM3 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-VD4)/pVD10 
KanR, ThioR This thesis 
S. coelicolor M512 
(nov-VD7) 
S. coelicolor M512 containing nov-BG1 
with the region from novD stop codon to 
novH start codon replaced by apra-tcp830; 
KanR, ApraR 
This thesis 
S. coelicolor M512 
(nov-VD8) 
S. coelicolor M512 containing nov-BG1
with the intergenic region novP_novQ
replaced by apra-tcp830; KanR, ApraR 
This thesis 
S. coelicolor M512 
(nov-VD9) 
S. coelicolor M512 containing nov-VD7 
with the intergenic region novP_novQ
replaced by apra-tcp830; KanR, ApraR 
This thesis 
S. coelicolor M512 
(nov-JH4) 
S. coelicolor M512 containing a ΩnovH
novobiocin cluster; KanR; ApraR 
Johannes Härle´s 
Thesis 
 
II.5.6. Probe used in Southern blot analysis 
Cosmid nov-BG1 after digestion with PstI and DIG-labelling, was used as probe for 
Southern blot analysis. 
 
II.6. Culture conditions 
II.6.1. Cultivation of E. coli 
For cloning experiments, E. coli strains were grown overnight (16-18 h) in liquid or 
solid LB medium with appropriate antibiotic(s) at 37 °C (Sambrook & Russell, 2001). 
Permanent cultures of E. coli were prepared by mixing 600 µl of overnight culture 
with 400 µl of glycerol solution (50% (w/v) in distilled water) and stored at -70°C. 
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II.6.2. Cultivation of Streptomyces coelicolor 
II.6.2.1. General cultivation 
Streptomyces coelicolor strains were routinely cultured in liquid YMG medium. These 
cultures were carried out by inoculation of 108 spores into 300 ml baffled Erlenmeyer 
flasks containing a stainless steel spring and 50 ml YMG medium and cultivated at 
200 rpm and 30 °C for 48 hours. For preparation of protoplasts, S. coelicolor was 
cultured in TSB medium containing 0.4% glycine. For isolation of genomic DNA,       
S. coelicolor  was cultured in TSB medium. An appropriate concentration of 
antibiotic(s) was added, if required. 
 
II.6.2.2. Production of secondary metabolites 
 
For production of secondary metabolites S. coelicolor strains containing the entire or 
modified novobiocin biosynthetic gene cluster were cultivated in 300 ml baffled 
Erlenmeyer flasks or 24-square deepwell plates. 
 
Note: Cultivation of Streptomyces coelicolor strains in 24-square deepwell plates 
(Duetz et al., 2000) resulted in higher reproducibility of cell growth and novobiocin 
production in comparison to conventional Erlenmeyer flask cultivations. Therefore, 
cultivation in 24-square deepwell plates are recommended especially for quantitative 
analysis of secondary metabolite production and (q)RT-PCR experiments. 
Cultivation in Erlenmeyer flasks 
For production of secondary metabolites, 1ml of the YMG preculture of S. coelicolor 
containing the entire or modified novobiocin gene cluster was inoculated into 300 ml 
baffled flasks containing a stainless steel spring and 50 ml CDM production medium 
and cultivated at 30 °C and 200 rpm for 7 days. The cultivation in production medium 
was carried out without addition of antibiotics. 
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Cultivation in 24-square deepwell plates 
For cultivation in 24-square deepwell plates frozen and homogenized inoculum of 
Streptomyces coelicolor strains were prepared as described in II.6.2.3.. 106 CFU of 
this inoculum was mixed with 40 ml CDM production medium, containing 0.6 % (m/v) 
siloxylated polyether EO/PO copolymer Q2-5247 (Dow Corning, Auburn, 
Michigan/USA) and 3 ml of this mixture were placed into each well of the 24-square 
deepwell plates (Duetz et al., 2000). Cultivation was carried out at 30 °C and 300 rpm 
for 7 days. This cultivation was carried out without addition of antibiotics. 
 
II.6.2.3. Preparation of homogenized and frozen inoculum 
For preparation of frozen inoculum, 50 ml of YMG preculture were centrifuged     
(2772 x g for 10 min). The cells were resuspended in 10 ml of an aqueous solution of 
20 % (w/v) peptone (Bacto® Proteose Peptone Nr. 3, Difco, Sparks, Maryland/USA) 
and gently homogenized using a potter homogenizer operated manually (B. Braun 
Biotech, Sartorius AG, Göttingen, Germany). The resulting mixture was devided in 
aliquots and stored at -70 °C. 
 
II.6.2.4. Preparation of mycelia for storage and spore suspensions of 
Streptomyces 
For preparation of mycelia for storage, 1 ml 2-day-old YMG culture was harvested by 
centrifugation and the cells were resuspended in 0.5 ml 20 % glycerol. The storage 
was carried out at -70°C.  
To prepare spore suspensions, Streptomyces coelicolor strains were spread on MS 
agar and incubated at 30 °C for about one week. The plates (one to two plates for 
good sporulaters, four for more sparely sporulating strains) were grown till they were 
well sporulated. 4 ml of Tween® 20 (0.1% (w/v)) were added to each plate and the 
spores scraped off of the top of the plates and into suspension. The resulting spore 
suspension was poured into a falcon tube and vortexed vigorously (about 1 min). The 
spores were separated from the mycelium by passing the suspension through sterile 
cotton pluged in a disposable syringe. Spores were collected by centrifugation 
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(2,100×g, 10 min, 4 °C), and resuspended in 1-3 ml of 20% glycerol. The spore 
suspensions were kept at -70 °C. 
Note: For selection of Streptomyces coelicolor strains with thiostreptone as selection 
marker, strains were spread on MM agar ! 
 
II.7. Methods of molecular biology 
II.7.1. Purification, concentration and quantification of DNA 
Standard methods for DNA isolation and manipulation were performed as described 
elsewhere (Kieser et al., 2000; Sambrook & Russell, 2001).  
Phenol/chloroform extraction and ion exchange column chromatography were used 
for purification of DNA. Ethanol or isopropanol precipitation was used for 
concentration.  
Quantification of DNA was carried out by using a GeneQuant photometer (Pharmacia, 
Freiburg, Germany) at 260 nm as well as by comparing the fluorescent intensity with 
DNA markers on agarose gels. 
II.7.2. Agarose gel electophoresis of DNA 
Gel electrophoresis with 0.8-1.5% (w/v) agarose was used to separate DNA 
fragments between 0.5 and 50 kb, and with 2-2.5% NuSieve®GTG® agarose to 
separate DNA fragments between 0.1 and 0.5 kb. The buffer system employed was 
1×TAE buffer (Table II.8). After running the gels, they were stained with the 
fluorescent dye ethidium bromide, detected under the UV light at 312 nm and 
photographed by using Eagle Eye II System (Strategene, Heidelberg, Germany) 
(Sambrook & Russell, 2001). 
DNA fragments were isolated from agarose gels using a NucleoSpin® 2 in 1 
extraction kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
protocol. 
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II.7.3. DNA manipulation with enzymes 
Restriction of DNA with endonucleases was carried out according to the 
manufacturer's instructions.  
DNA ligation was achieved by using T4-DNA ligase. The ligation preparation, 
containing 1U T4 DNA ligase, 1×ligation buffer and a 1:1 (mole ratio) mixture of insert 
and linearized vector (about 100 ng) in a final volume of 10 µl, was incubated at room 
temperature for 2 h or at 16 °C or 4 °C overnight. 
II.7.4. DNA isolation 
II.7.4.1.  Isolation of plasmids from E. coli 
Mini-preps employing alkaline lysis were used to isolate recombinant plasmids from E. 
coli for routine screening. 3 ml LB-medium was inoculated with a single colony and 
grown overnight at 37 °C, 170 rpm. 2 ml of this culture were harvested by 
centrifugation (10000×g, 4 °C, 1 min) and resuspended in 250 µl solution MP1 by 
vortexing. The suspension was mixed with 250 µl solution MP2 by inversion and 
incubated at room temperature for 1-5 min. 250 µl solution MP3 was added and the 
mixture was incubated on ice for 5 min. After centrifugation (20,000×g, 4 °C, 15 min), 
the supernatant was poured into a fresh microfuge tube. The DNA was precipitated 
by addition of 0.8-fold isopropanol and centrifugation (20,000×g, 4 °C, 30 min). The 
DNA pellet was washed with 500 µl 70% ethanol, air dried and resuspended in 50 µl 
distilled water or TE buffer. The mentioned solutions are listed in Table II.5. 
Preparative isolation of plasmids from E. coli was carried out with ion-exchange 
columns (Nucleobond® AX100, Macherey-Nagel, Düren, Germany) according to the 
manufacter´s protocol.  
II.7.4.2.  Isolation of plasmids from Streptomyces 
Isolation of plasmid DNA from Streptomyces strains was carried out by alkaline lysis 
and potassium acetate precipitation, adapted from procedure D (Kieser et al., 2000). 
2 ml of a 2-day-old culture in YMG medium were harvested by centrifugation 
(17,000×g, 4 °C, 1 min). After washing with 1ml of solution MP1, the cells were 
resuspended in 500 µl of solution MP1GL by vortexing. The suspension was 
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incubated at 37 °C for 30-60 min, then mixed with 500 µl of solution MP2 by inversion 
and incubated at room temperature for 10 min. 400 µl solution MP3 and 40 µl 
Rotiphenol® were added and mixed by inversion. The mixture was incubated on ice 
for 5 min. After 20 min centrifugation (20,000×g, 4 °C), the supernatant was poured 
into a fresh microfuge tube and extracted twice with 300 µl 
Phenol/Chloroform/Isoamylalcohol (25:24:1). The DNA was precipitated by addition 
of 0.8-fold volume of isopropanol and centrifugation (20,000×g, 4 °C, 20 min). The 
DNA pellet was washed with 500 µl 70% ethanol, air dried and resuspended in 20 -  
50 µl distilled water or TE buffer. If required, the plasmid DNA isolated from 
Streptomyces was amplified in E. coli XL1 blue MRF´ before restriction analysis. The 
mentioned solutions are listed in Tables II.5 and II.6. 
II.7.4.3.  Isolation of genomic DNA from Streptomyces coelicolor 
Genomic DNA was isolated by the Kirby mix procedure (Kieser et al., 2000). 2 ml of a 
2-day-old culture in TSB medium were harvested by centrifugation (17,000×g, 4 °C,   
1 min). The cells were washed with 1 ml TSE buffer and resuspended in 500 µl TSE 
buffer with lysozym (3 mg/ml) and RNase A (100 µg/ml) by vortexing. The 
suspension was incubated for 15 min at 37 °C. 400 µl of 2×Kirby mix were added and 
the mixture was vortexed vigorously for 1 min. 800 µl phenol/chloroform/isoamyl 
alcohol (25:24:1) were added and the mixture was vortexed vigorously for 15 s and 
centrifuged at 17,000×g and 4 °C for 10 min. The supernatant was poured into a 
fresh microfuge tube and extracted a second time with addition of 70 µl “unbuffered” 
3 M NaOAc and 300 µl phenol/chloroform/isoamyl alcohol (25:24:1) (1 min vigorous 
vortexing). The aqueous phase was separated and genomic DNA was precipitated by 
addition of 0.8-fold volume of isopropanol and centrifugation (20,000×g, 4 °C, 30 min). 
The DNA pellet was washed with 500 µl 70% ethanol, air dried and resuspended in 
50 to 100 µl TE buffer. 
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II.7.5. DNA denaturation by alkaline treatment for ssDNA transformation in 
Streptomyces 
9 µl dsDNA in H2O was mixed with 2 µl 1 M NaOH and incubated for 10 min at 37 °C. 
The mixture was placed on ice and the reaction was terminated with addition of 2 µl  
1 M HCl (Oh & Chater, 1997). 
 
II.7.6. PCR amplification 
II.7.6.1. General conditions  
PCR amplifications were carried out with the GeneAmp® PCR System 2400 or 
GeneAmp® PCR-System 9700 (Perkin-Eimer, Weiterstadt, Germany) or iCycler PCR-
System (Bio-Rad, Munich, Germany). The amplification conditions for PCR reactions 
using the Expand High Fidelity PCR system (Roche) are given in Table II.19, and 
using the GC-Rich PCR system (Roche) in Table II.20.  
TABLE II.19: PCR reaction and amplification conditions using the Expand High 
Fidelity PCR system 
Substance Final concentration  Cyclus Temperature Time Cycles 
Reaction buffer 
(10) 
1  Hot start 94 °C 2 min 1 
DMSO  5% (v/v)  Denaturing 94 °C 45 s 
Template DNA about 100 ng  Annealing 50-60 °C 45 s 
dNTPs 0.2 mM each  Elongation 72 °C 90 s 
30 
Primer  50 pmol each  Final elongation 72 °C 5 min 1 
DNA-Polymerase 2.5 U  End 4 °C  1 
Add distilled water to make up to 50 l      
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TABLE II.20: PCR reaction and amplification conditions using the GC-Rich PCR 
system  
Substance Final concentration  Cyclus Temperature Time Cycles 
GC-Rich PCR 
reaction buffer with 
DMSO (5) 
1  Hot start 95 °C 5 min 1 
 Denaturing 95 °C 90 s GC-Rich resolution 
solution (5 M) 
0.5 mM 
 Annealing 55-60 °C 90 s 
dNTP-Mix 0.2 mM each 
 Elongation 72 °C 45s/ 1 
kb 
30 
Primer 1 20 pmol  Final elongation 72 °C 5 min 1 
Primer 2 20 pmol  End 4 °C  1 
Template DNA about 100 ng      
GC-Rich PCR 
System enzyme 
mix 
2 U      
Add distilled water to make up to 100 l      
For PCR amplification with Taq or Pfu polymerase, the PCR mixture (50-100 µl) 
contained 50 pmol each primer, 100-300 ng template DNA, 0.2 mM each dNTP, 1× 
reaction buffer, 5% (v/v) DMSO and 2-3 U polymerase. Amplification conditions were 
according to the supplier’s instructions. 
In general, 5 to 10 µl of the PCR reaction were analysed by gel electrophoresis. 
 
II.7.6.2. Conditions for amplification of the apramycin resistance cassette 
from pUG019 and the apra-tcp830 cassette from pMS80  
The conditions for amplification of the apra-tcp830 from pMS80 (REDIRECT© 
technology kit for PCR targeting (Gust et al., 2003)) using the Expand High Fidelity 
PCR system (Roche) are given in Table II.21. Template DNA was prepared by 
digesting about 10 µg of pMS80 with KpnI and SacII, and by isolating the 1.7 kb 
cassette fragment from an agarose gel (Gust et al., 2003). 
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TABLE II.21: Conditions for amplification of the apramycin resistance cassette 
from pUG019 and apra-tcp830 from pMS80 
Substance Final concentration  Cyclus Temperature Time Cycles 
Reaction buffer 
(10) 
1  Hot start 94 °C 2 min 1 
DMSO  5% (v/v)  Denaturing 94 °C 45 s 
Template DNA about 100 ng  Annealing 50 °C 45 s 
dNTPs 0.2 mM each  Elongation 72 °C 90 s 
10 
Primer  50 pmol each  Denaturing 94 °C 45 s 
DNA-Polymerase 2.5 U  Annealing 55 °C 45 s 
Add distilled water to make up to 50 l  Elongation 72 °C 90 s 
15 
   Final elongation 72 °C 5 min 1 
   End 4 °C  1 
For amplification of the apramycin resistance cassette from pUG019 the conditions 
were the same as listed in Table II.21. Template DNA was prepared by digesting 
about 2 µg of pUG019 with EcoRI, HindIII and DraI (DraI cuts three times in the 
vector backbone, and it is used to guarantee the destruction of traces of cccDNA and 
to avoid purification of the cassette by gel electrophoresis). After digestion, the 
mixture was purified and concentrated by isopropanol precipitation. 
 
II.7.7. Southern blot analysis 
Southern blot analysis was performed on Hybond-N membranes (Amersham) by 
using the DIG high prime DNA labelling and detection starter kit II (Roche). Buffers 
and solutions are given in Table II.9.  
Note: powder-free gloves were always worn to handle the used plastic or glass ware 
and the membrane (which should, if possible, only be handled with a pair of clean 
tweezers on the edges). Plastic and glass ware were thoroughly washed with distilled 
water before use. 
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II.7.7.1. Probe preparation 
Probe for Southern hybridization was prepared by the random priming method using 
the DIG high prime DNA labelling and detection starter Kit II (Roche) according to the 
user’s manual. The probe used in this thesis is presented in section II.5.6. 
II.7.7.2. Southern blot preparation 
An agarose gel with DNA digested with appropriated enzymes and the DIG Molecular 
Weight Marker VII (Roche) was run. The gel was stained with ethidium bromide and 
photographed. The DNA was denaturized by soaking the gel in denaturing buffer for 
215 min, and then neutralized by soaking in neutralizing buffer for 2  15 min, with 
gentle agitation. Southern blot was carried out by capillary transfer using 20SSC 
buffer. For this purpose, the gel was placed on pre-wetted (in 20SSC buffer) filter 
paper and overlaid with pre-wetted (in 2SSC buffer) Hybond-N nylon membrane and 
pre-wetted (in 20SSC buffer) filter paper. About 7 cm paper towels and a 1 kg 
weight were stacked on the top. The transfer was carried out overnight. The 
membrane was then crosslinked with UV light (312 nm, 60 s on the front side and    
30 s on the backside) and washed with sterile, distilled water. The membrane was 
used immediately or stored at 4 ºC after air drying.  
II.7.7.3. Prehybridization and hybridization  
The membrane was incubated in prehybridization solution (20 ml/100 cm2) for 4 h at 
68 °C with gentle rotation. Appropiate probe was added to the hybridization solution 
(5-25 ng/ml). This was denaturized by heating (10 min in a boiling water bath), and 
immediately chilled in liquid nitrogen. The prehybridization solution was replaced by 
the hybridization solution containing the appropriate probe (about 7 ml/100 cm2) and 
incubated overnight at 68 °C.  
II.7.7.4. Detection 
The membrane was washed twice with 2washing buffer for 10 min at room 
temperature, and afterwards twice with 0.5washing buffer at 68 °C for 20 min, with 
gentle rotation. After equilibration in maleic acid buffer for 5 min, the membrane was 
incubated with blocking solution for 30 min and then with antibody solution for 30 min. 
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To remove excess of antibody, the membrane was washed twice in Tween® washing 
buffer, 15 min each at room temperature. Finally, the membrane was equilibrated in 
detection buffer for 5 min and immediately placed between two plastic sheets (which 
were sealed in two sides) with the backside of the membrane placed on one sheet, 
and the front side remaining free by lifting the second sheet. A 1:100 dilution of 
CSPD stock solution in detection buffer was dropped onto the membrane (0.5 
ml/100cm2) and spread over it by letting down the second sheet. It was incubated at 
room temperature for 2-5 min protected from light. Excess of solution and air bubbles 
were removed by wiping the cover sheet with a clean paper towel. The membrane 
was exposed to a Hyperfilm ECL-X-ray film (Amersham Biosciences, Freiburg, 
Germany) at 37 °C for 30 min to 3 h, depending on the strength of the signal. The 
film was developed using standard methods. 
II.7.7.5. Removal of probe 
If necessary, probe was removed by washing the membrane twice with stripping 
solution for 15 min at 37 °C, followed by washing with 2SSC solution for 30 min at 
room temperature. After that, the membrane could be used for further hybridization or 
stored in 2SSC solution at 4 °C. 
II.7.8. Introduction of DNA in E. coli  
The methods described in this section were modified from (Sambrook & Russell, 
2001). 
II.7.8.1. CaCl2-mediated transformation 
Preparation of competent cells: 100 ml LB-medium were inoculated with 1 ml of an 
overnight culture of E. coli and cultivated at 37 °C and 170 rpm till the OD600 reached 
0.6 (2.5-4 h). The cells were harvested by centrifugation (3,000×g, 4 °C, 5 min), 
resuspended in 30 ml ice-cold 0.1 M MgCl2 and again centrifuged as above. The cell 
pellet was suspended in 20 ml ice-cold CaCl2 (0.1 M) and incubated on ice for 20 min. 
After centrifugation, the pellet was suspended in 5 ml of CaCl2 (0.1 M) solution 
containing 15% glycerol. Competent cells could be used immediately or dispensed in 
200 µl aliquots in 1.5-ml microfuge tubes, and stored at -70 °C.  
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Note: Resuspension of cells should not be done by vortexing. Therefore, it is easier 
and quicker to resuspend the cells first in the remaining drops (after discarding the 
supernatant) by tapping the tube, and only afterwards to add the required solution 
and mix gently by inversion. 
Transformation: DNA (0.1-1 µg in 1-5 µl) was added to 100-200 µl competent cells 
in 1.5-ml microfuge tube and incubated on ice for 30 min. The tube was then 
incubated at 42 °C for 2 min and cooled down on ice (about 5 min). 1 ml LB medium 
was pipetted into the tube, and the suspension was incubated on a water bath or on 
a shaker (170 rpm) for 1 h at 37 °C. 200 µl of the mixture were spread on a LB agar 
plate containing the appropriate antibiotic(s) and the rest was centrifuged (17,000×g, 
4 °C, 30 s), resuspended in 200 µl LB and spread on another LB agar plate. The 
plates were incubated at 37 °C. For transformation of E. coli XL1 Blue MRF’ cells 
with a circular plasmid (cccDNA), the incubation on ice might be shortened to 10 min 
and the incubation with LB medium at 37 °C might be omitted, since the 
transformation efficiency is otherwise too high to allow growth of single colonies. 
However, for E. coli ET12567, all the procedure as described above should be 
carried out, as the transformation efficiency of this strain is lower (about 100-fold). 
Blue/white selection: If a lacZ-containing cloning vector was used to prepare the 
recombinant plasmid, blue/white selection can facilitate the identification of the 
expected clones. For this purpose, first 15 µl of IPTG solution (80 mg/ml) in up to 100 
µl H2O (sterile) were pipetted on the top of the plates and spread evenly, and then 60 
µl of X-Gal solution (20 mg/ml in DMF) was plated in the same way. The plates were 
air dried under the laminar flow for 30-45 min in order to evaporate the toxic DMF. 
Colonies containing the recombinant plasmid lack -galactosidase activity and 
remain white. 
II.7.8.2. Electroporation 
Preparation of electro-competent cells: 50 ml LB-medium was inoculated with 1 ml 
of an overnight culture of E. coli and cultivated at 30 to 37 °C (see note below), 170 
rpm till the OD600 reached 0.6 (2.5-4 h). The cells were harvested by centrifugation 
(3,000×g, 4°C, 5 min), and washed twice with 50 and 25 ml ice-cold 10% (w/v) 
glycerol solution, respectively. The cell pellet was suspended in the remaining drops 
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after discarding the supernatant. Competent cells could be used immediately or 
dispensed in 50-µl aliquots in 1.5-ml microfuge tubes, and stored at -70 °C.  
Electroporation: DNA (about 100 ng in 1-2 µl distilled water) was added to 50 µl 
competent cells in 1.5-ml microfuge tube and incubated on ice for about 1 min. The 
mixture was then carefully transferred to an ice-cold electroporation cuvette (0.2 cm), 
avoiding formation of air bubbles, and electroporation was carried out using a BioRad 
electroporator set to 2.5 kV. The optimal time constant is 4.5 – 5.0 ms. 1 ml LB 
medium was immediately pipetted into the cuvette, and the suspension was 
transferred to a microfuge tube and incubated on a water bath or on a shaker (170 
rpm) for 1 h at 30 to 37 °C. The mixture was spread on LB agar plates containing the 
appropriate antibiotic(s) (no more than 200 µl per plate) and the plates were 
incubated at 30 to 37 °C. 
Note: To maintain plasmid pIJ790 in E. coli BW25113 (REDIRECT© technology kit for 
PCR targeting (Gust et al., 2003)), cells must be cultured at 30 °C, since pIJ790 
contains a temperature sensitive origin of replication. Otherwise, the cultivation 
temperature was 37 °C. 
 
II.7.9. PEG-mediated protoplast transformation for introduction of DNA in 
Streptomyces 
Relevant buffers and media are listed in Table II.11 and in section II.4.1.4, 
respectively. 
Preparation of protoplasts from S. coelicolor 
Slightly modified from (Kieser et al., 2000). Mycelium from a 40 h old culture (50 ml 
TSB medium containing 0.4 % glycine) was washed twice with 15 ml of a 10.3% 
sucrose solution, resuspended in 10 ml of lysozyme solution (2 mg/ml in P buffer) 
and incubated at 30 ºC for 15-60 min with gentle agitation. Protoplast formation was 
monitored using the microscope. After most cells became protoplasts, the reaction 
was stopped by incubation on ice. The following steps were carried out on ice. 10 ml 
of ice-cold P buffer were added and the suspension was drawn in and out of a 10 ml 
pipette three times and filtered through glass wool. Protoplasts were sedimented 
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gently by centrifugation (e.g. 1,000xg, 7 min). The supernatant was discarded, the 
pellet was first carefully resuspended in the remaining drop of liquid by tapping the 
tube, and then in 1 ml P buffer. The protoplast suspension can be immediately used 
for transformation or 100 µl aliquots can be stored at -70 ºC. To freeze protoplasts for 
storage, tubes were placed in ice contained in a plastic beaker, and the beaker was 
placed at -70 ºC overnight. To assess the protoplast regeneration, dilution series of 
the protoplast suspension in P buffer were prepared and plated on R5 agar plates 
(see note below). The plates were incubated at 30 °C for 3-7 days. The regenerable 
protoplasts per ml suspension were calculated. To assess the proportion of non-
protoplasted units in the suspension, samples were also diluted in distilled water and 
plated on regeneration plates (R5 agar).  
Note: plating of protoplasts was always done by overlaying with R5 soft agar instead 
of spreading in order to avoid mechanical stress and lysis. 
Transformation: The transformation of Streptomyces strains was carried out by a 
modification of the method described by Kieser et al. (2000).  
Before transformation of Streptomyces strains the plasmids were propagated in E. 
coli ET 12567 to bypass methyl-sensing restriction.  
1-20 µg DNA (in maximal 10-20 µl TE buffer) were added to 100-200 µl of a 
protoplast suspension, containing at least 108 protoplasts per ml; 400-500 µl T-buffer 
containing PEG 1000 (25% (w/v) were immediately added, mixed by pipetting 
carefully three times and incubated at room temperature for 1 min. Increasing 
volumes of the resulting suspension (e.g. 10 µl, 100 µl, 200 µl, rest) were mixed with 
warm R5 soft agar (about 50 °C, 4×3 ml) and plated on four R5 plates. After 16-24 h 
incubation at 30 °C, the plates were overlaid with 3 ml of R5 soft agar including the 
required antibiotics for selection of mutants, and incubation was continued for further 
3-7 days.  
II.7.10. DNA sequencing and computer-assisted sequence analysis 
Double-stranded sequencing of recombinant plasmids was done by the 
dideoxynucleotide chain termination method on a LI-COR automatic sequencer 
(MWG-Biotech AG, Ebersberg, Germany). 
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The DNASIS software package (Version 2.1, Hitachi Software Engineering, San 
Bruno, CA, USA) was used for sequence analysis. Amino acid sequence homology 
searches were performed by using the BLAST program (Version 2.0) available on the 
web at www.ncbi.nim.nih.gov/BLAST/. 
 
II.8. RNA methods 
II.8.1. RNA isolation, DNase treatment and purification 
For RT-PCR experiments Streptomyces coelicolor M512 strains were cultivated in 
300 ml baffled Erlenmeyer flasks as described above. From each mutant 1 ml of 
YMG preculture was inoculated into a 300 ml baffled flask containing 50 ml CDM 
production medium (Kominek, 1972) and cultivated at 30 °C and 200 rpm. After 22, 
30, 44, 77 and 94 hours of cultivation the mycelia of 50 ml culture was collected by 
vaccum filtration, followed by rinsing with 30 ml distilled water. 
 
Note: Cultivation of Streptomyces coelicolor M512 strains for RT-PCR experiments 
were carried out in Erlenmeyer flasks because at this time point the cultivation 
procedure in 24-square deepwell plates was not established. Everyone working on 
regulation projects is recommended to carry out cultivation in 24-square deepwell 
plates (see below) due to its very stable and reproducible cell growth and production! 
 
For qRT-PCR experiments Streptomyces coelicolor strains were cultivated in 24-
square deepwell plates (Duetz et al., 2000) as described above. From each mutant 2 
x 106 CFU of frozen inoculum were mixed with 80 ml CDM production medium, 
containing 0.6 % (m/v) siloxylated polyether EO/PO copolymer Q2-5247 (Dow 
Corning, Auburn, Michigan/USA) and 3 ml of this mixture were placed into 27 wells of 
2 x 24-square deepwell plates. Cultivation was carried out at 30 °C and 300 rpm. 
After 24, 32, 48, 72 and 96 hours mycelia of 6 to 4 wells were pooled and collected 
by vacuum filtration, followed by rinsing with 30 ml distilled water. After 168 hours 3 
wells were harvested to analyze final novobiocin production. 
Then the cells were transferred to a universal plastic tube (50 ml falcon tube) 
containing appoximately 14 g 3.5 – 4.5 mm diameter glass beads and 15 ml of 
modified kirby mix Table II.12 and vortexed for 2 min. After that, cell suspension was 
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sonicated for 6 x 30 s with 20 s intervals between each sonication treatment 
(Branson sonifier 250). To this cell suspension 1 volume (15 ml) of 
phenol/chloroform/isoamylalcohol (25:24:1) was added and followed by vortexing for 
30 s and centrifugation (5000 x g for 10 min at 4 °C).  
 
Note: Due to the instability of RNA the following steps have to be carried out carefully 
to avoid contamination with RNAse. Therefore, gloves were always worn to handle 
the used plastic or glass ware. Plastic, glass ware, water and solutions (except from 
ethanol, isopropanol, modified kirby mix and phenol/chloroform/isoamylalcohol 
25:24:1) were autoclaved twice before use. Furthermore, breezing and talking into 
probes was avoided. 
 
Clear supernatant was transferred to a clean tube (50 ml falcon tube) and mixed with 
an equal volume of isopropanol and 0.1 volume 3 M sodium acetate (pH: 5.2) and 
leaved for 5 min at 20 °C. After centrifugation (5000 x g for 20 min at 4 °C) 
supernatant was discarded and the pellet was washed with 2 ml ethanol 70 % (v/v). 
Then pellet was dried and resuspended in 800 µl water. After resuspension DNase 
treatment was carried out, using Deoxyribonuclease I (1U µl-1), 10 x buffer with MgCl2 
(100 mM Tris-HCl (pH 7.5 at 25 °C, 25 mM MgCl2, 1mM CaCl2) and RNase-free 
water (Fermentas) according to manufacturer´s instructions. After that, RNA was 
purified with the NucleoSpin® RNA Clean-up Kit (Macherey & Nagel) according to 
manufacturer´s instruction and eluted from the column with 40 µl water, followed by 
its quantification by determining the OD at 280 nm. Integrity of RNA was checked by 
running 1 µg of RNA on a 1.2 % agarose gel. To ensure that RNA is free of DNA, 
PCR using RNA-probes without previous RT-reaction (PCR-conditions and primers 
as presented below; concentration tenfold to the concentration that was used in RT-
reaction) was carried out. 
 
II.8.2. RT-PCR 
After ensuring that RNA is free of DNA the RT-reaction was carried out. Therefore 
random hexamer primers (0.2 µg µl-1), 5 x reaction buffer (250 mM Tris-HCl (pH: 8.3 
at 25 °C), 250 mM KCl, 20 mM MgCl2, 50 mM DTT), RiboLock™ Ribonuclease 
Inhibitor (20U µl-1), 10 mM dNTP mix (10 mM each), RNase-free water and 
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RevertAid™M-MuLV Reverse Transcriptase (200U µl-1)  (Fermentas) were used. RT-
reaction was carried out according to the Fermenta´s “Protocol for First Strand cDNA 
Synthesis”. 
 
After RT-reaction PCR using primer pairs for amplication of hrdB, novE and novG 
listed in Table II.16 was carried out in 50 µl volume with 2 µl template (cDNA from 
RT-reaction), 2.5 mM dNTPs each, 50 pmol each primer, 5 % (v/v) DMSO, 10 x 
buffer (100mM Tris-HCl, pH: 8.8 at 25 °C; 500 mM KCl, 0.8 % (v/v) Nonidet P40 and 
15 mM MgCl2) and 1 µl Taq DNA-polymerase (1U µl-1): denaturation at 95 °C for 2 
min; 27 cycles with denaturation at 95 °C for 30 s, annealing at 70 °C for 30 s and 
extension at 72 °C for 50 s, and a final elongation step at 72 °C for 7 min. Finally 
PCR product was checked by running 22 µl of the PCR-reation with 8 µl loading 
buffer [50% glycerol, 200mM EDTA, 0.5 % xylen cyanol(Sigma®)] on a 1.2 % 
agarose gel. 
 
II.8.3. qRT-PCR 
LightCycler® quantitative RT-PCR (qRT-PCR) was carried out using the LightCycler® 
RNA ampflication Kit SYBR Green I (Roche). Master mixes were prepared by 
following the manufacturer´s instructions for GC-rich templates except from [MgCl2] 
that was reduced to 6.25 mM for investigations on novE, novF, novG, novH, novO, 
novQ and gyrBR and 12.5 mM for inverstigations on hrdB and novP, using the 
primers listed in Table II.17. After RT for 20 min at 50°C, the following temperature 
profile was utilized for amplification: denaturation for 1 cycle at 95 °C for 30 s and 45 
cycles at 95 °C for  1 s (temperature transition, 20 °C/s), 60 to 55 °C (novE, novG, 
novH, novO), 58 to 53 °C (hrdB, novQ), 56 to 52 °C (novF, novP, gyrBR) (step size, 
0.7°C; step delay, 1 cycle) for 10 s (temperature transition, 20 °C/s), and 72 °C for 13 
s (temperature transition, 2 °C/s) with stepwise fluorescence acquisition at 60 to 55 
°C in single mode. The number of copies of each sample transcript was then 
determined with the aid of LightCycler® software and normalised to hrdB. The 
specificity of the PCR reaction was verified by ethidium bromide staining on 2% 
agarose gels. 
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II.9. Heterologous expression of the modified novobiocin 
biosynthetic gene clusters 
II.9.1. Inactivation of novE in cosmids nov-BG1 and nov-AE10, and 
heterologous expression of the ΔnovE and ΔnovEΔnovG cosmid 
 
The gene novE in cosmid nov-BG1 and cosmid nov-AE10 (ΔnovG cosmid) 
(Eustáquio et al., 2005b) was replaced by the apramycin resistance (aac(3)IV) 
cassette from pUG019 (Eustáquio et al., 2004) via λ-Red-mediated recombination 
(Gust et al., 2003) resulting in cosmid nov-VD1 (from nov-BG1) and nov-VD3 (from 
nov-AE10). This cassette is flanked by the FRT (FLP recognition target). The 
cassette for replacement of novE was generated by PCR using the primer pair 
P1_novE (5´-CGC CGG TCC GCT TGT CCC GAG GGG AAG AGA GGC ATC GTG 
ATT CCG GGG ATC CGT CGA CC-3´)  and P2_novE (5´-GCC GTG AGG CCG 
CGA AAT GGA TCG GAG TGC GTC CGG TCA TGT AGG CTG GAG CTG CTT C-
3´). Bold letters respresent 39 nt homologous extensions to the DNA regions 
immediately upstream and downstream of novE, including the putative translational 
start and stop codons of novE, respectively. The PCR reaction was performed in 50 
µl volume with 50 ng template (pUG019 digested with EcoRI, HindIII and DraI), 0.2 
mM dNTPs, 50 pmol each primer, 5 % (v/v) DMSO, using the Expand High Fidelity 
PCR System (Roche Molecular Biochemicals): denaturation at 94 °C for 2 min, then 
10 cycles with denaturation at 94 °C for 45 s, annealing at 50 °C for 45 s, and 
extension at 72 °C for 90 s, then 15 cycles with annealing at 55 °C, and a final 
elongation step at 72 °C for 5 min. Subsequently, the cassette was excised by the 
FLP recombinase, leaving an in-frame “scar” of 81 nucleotides between the start and 
stop codon of novE, resulting in cosmid nov-VD2 (ΔnovE) and nov-VD4 
(ΔnovEΔnovG). E. coli XL1 Blue MRF´ cells were analysed using restriction enzymes 
and gel electrophoresis. The generated ΔnovE cosmid (nov-VD2) and ΔnovEΔnovG 
cosmid (nov-VD4), carrying the kanamycin resistance gene neo, were then 
introduced into S. coelicolor M512 by PEG-mediated protoplast transformation 
(Kieser et al. 2000). Kanamycin resistant clones were checked for specific genomic 
integration of cosmid nov-VD2 or cosmid nov-VD4 into the ΦC31 attachment site by 
Southern blot analysis. 
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II.9.2. Introduction of tcp830 into cosmid nov-BG1 and heterologous 
expression of the resulting cosmids 
 
The apramycin-tcp830 cassette (apra-tcp830) from pMS80 (Rodriguez-Garcia et al., 
2005) was introduced in nov-BG1 via λ-Red-mediated recombination (Gust et al., 
2003), either in exchange with the region from novD stop codon to novH start codon, 
resulting in cosmid nov-VD6 or by replacing the intergenic region novP_novQ, 
resulting in cosmid nov-VD8. The apramycin resistance gene (aac(3)IV) is flanked by 
the FRT (FLP recognition target). The required cassettes were generated by PCR 
using the primer pairs P_novD_apra-tcp830 (5´-AAC CCG GAC CGG TAC GTA 
CGG CTG AGC TTC CTC GGC TGA ACT AGT GTG TAG GCT GGA GCT GCT TC-
3´) and P_novH_apra-tcp830 (5´-CGA CTG ATC AGA AGC TTT GTT CGC ACG 
TGT GTT GAA CAA TCT AGA CCT CCG ACG TAC GC -3´) for replacement of the 
region from novD stop codon to novH start codon, and P_novP_apra-tcp830 (5´-ATC 
GAC CGC GAC GGT GTC TAC TGG CAA CGC ACC CGG TAA ACT AGT GTG 
TAG GCT GGA GCT GCT TC-3´) and P_novQ_apra-tcp830 (5´- TTC GCG GTC 
GAA TTC TTG ATT CAT CGG GAG TGC GGG CAT TCT AGA CCT CCG ACG 
TAC GC-3´) for replacement of the intergenic region novP_novQ. Bold letters 
respresent 39 nt homologous extensions to the DNA regions immediately upstream 
of novD stop codon and downstream of novH start codon or upstream of novP stop 
codon and downstream of novQ start codon, including the putative translational stop 
codons of novD and novP and start codons of novH and novQ, respectively.  
 
The PCR reaction was performed in 50 µl volume with 50 ng template (pMS80 
digested with KpnI and SacII), 0.2 mM dNTPs, 50 pmol each primer, 5 % (v/v) DMSO, 
using the Expand High Fidelity PCR System (Roche Molecular Biochemicals): 
denaturation at 94 °C for 2 min, then 10 cycles with denaturation at 94 °C for 45 s, 
annealing at 50 °C for 45 s, and extension at 72 °C for 90 s, then 15 cycles with 
annealing at 55 °C, and a final elongation step at 72 °C for 5 min. Subsequently, nov-
VD6 was modified by excision of aac(3)IV by the FLP recombinase, leaving an in-
frame “scar” of 81 nucleotides between the stop codon of novD and tcp830, resulting 
in cosmid nov-VD7. For construction of nov-VD9, cosmid nov-VD8 was digested with 
KpnI and SacII and the obtained 4551 bp restriction fragment comprising the region 
from 671 bp upstream of novN stop codon to 525 bp downstream of novQ start 
codon, including the apra-tcp830 cassette from pMS80 in exchange with the 
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intergenic region novP_novQ was introduced into cosmid nov-VD7 via λ-Red-
mediated recombination (Gust et al., 2003). E. coli XL1 Blue MRF´ cells were 
transformed with 100 ng DNA and the obtained clones analysed using restriction 
enzymes and gel electrophoresis. The generated cosmids nov-VD7, nov-VD8 and 
nov-VD9, carrying the kanamycin resistance gene neo, were then introduced into S. 
coelicolor M512 by PEG-mediated protoplast transformation (Kieser et al., 2000). 
Kanamycin and apramycin resistant (nov-VD8 and nov-VD9) and kanamycin 
resistant clones (nov-VD7) were checked for specific genomic integration of the 
respective cosmids into the ΦC31 attachment site by Southern blot analysis. 
 
II.10. HPLC Analysis of secondary metabolites 
S. coelicolor strains carrying the (modified) novobiocin cluster were cultured in CDM 
medium as described in section II.6.2.2. After centrifugation, the clear supernatant 
was analysed by HPLC with a Multosphere RP18-5 column (150 x 4,6 mm; 5 µm; 
C+S Chromatographie Service, Düren, Germany) with a linear gradient from 60 to 
100% methanol in 1% aqueous formic acid and detection at 305 nm. Authentic 
novobiocin (Fluka) was used as standard. 
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III. RESULTS 
III.1. Investigations on the role of novE in the regulation of 
novobiocin biosynthesis and its interplay with novG 
III.1.1. Inactivation of novE 
 
In order to prove that novE is important for novobiocin biosynthesis, novE was 
inactivated by an in-frame deletion. For this purpose, novE was replaced in cosmid 
nov-BG1 with an apramycin resistance cassette flanked by FRT (FLP-recognition 
target) sites via λ RED-mediated recombination (Datsenko & Wanner, 2000; Gust et 
al., 2003) resulting in nov-VD1 (Fig. III.1c). The cassette was excised using FLP- 
recombinase, leaving an in-frame “scar” of 81 nucleotides between the start and stop 
codon of novE (Fig. III1c). This modified cosmid (named nov-VD2) was subsequently 
introduced into S. coelicolor M512 by protoplast transformation, and site-specific 
integration into the genome (Fig. III.1a and b) was confirmed by Southern blot 
analysis (Fig. III.1d). The deletion of novE was clearly shown by the size of the 
relevant PstI restriction fragments in comparison to nov-BG1 strains (Fig. III.1d, lane 
1 and 2). 
 
HPLC analysis showed that the resulting ΔnovE strains produced novobiocin in a 
strongly reduced amount (0.7 %) in comparison to S. coelicolor strains carrying the 
intact novobiocin cluster (Table III.1). Subsequently, novE together with its own 
putative promoter, i.e. including 599 bp upstream of the start codon of novE, was 
cloned into the promoterless shuttle vector pWHM3, resulting in pVD4. This plasmid 
was introduced into the ΔnovE strain S. coelicolor M512 (nov-VD2). Production levels 
of the resulting transformants reached up to 70 % of those observed in  S. coelicolor 
M512 (nov-BG1) which carries the intact novE gene. This proved that the very low 
novobiocin production of S. coelicolor M512 (nov-VD2) was indeed due to the 
inactivation of novE. 
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Fig. III.1: Inactivation of novE. See next page for details. 
.
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(a) Cosmid constructs nov-BG1 and nov-VD2. P = PstI restriction site; T3, T7 = T3 and T7 
promoter of the SuperCos1 vector, tet = tetracyclin resistance gene; neo = 
neomycin/kanamycin resistance gene; int, attP = integrase gene and attachment site of 
ΦC31. Fragment sizes resulting from digestion with PstI are indicated. Cosmid backbone out 
of scale. (b) Schematic representation of site specific integration of the cosmids into the 
genome of Streptomyces coelicolor M512. (c) Schematic presentation of novE replacement 
and deletion. novE (654bp) was first replaced by an apramycin resistance (aac(3)IV) 
cassette. Subsequently the cassette was excised using the FLP recombinase, leaving an in-
frame “scar” of 81 nucleotides between the start and stop codons of novE. FRT = FLP 
recognition target. oriT = origin for conjugative transfer. (d) Southern blot analysis. M = 
Molecular Weight Marker; Lane 1: Streptomyces coelicolor M512 (nov-VD2); lane 2: 
Streptomyces coelicolor M512 (nov-BG1); lane 3: Streptomyces coelicolor M512. Genomic 
DNA was digested with PstI. M = Molecular Weight Marker. The entire cosmid nov-BG1 was 
used as probe. 
 
Table III.1: Influence of novE and novG on novobiocin production in the heterologous host 
Streptomyces coelicolor M512. 
 
*Values are means from at least two independent mutants 
 
            Strain         Description      Expression plasmid          Novobiocin 
   (mg/l)               (%) 
S.coelicolor M512 control                      -      0                     0 
S.coelicolor(nov-BG1) complete cluster                       -     19.3              100 
S.coelicolor(nov-BG1) complete cluster pWHM3 (empty vector)     20.0              100       
S.coelicolor(nov-VD2) ΔnovE pWHM3 (empty vector)      0.14              0.7 
S.coelicolor(nov-BG1) complete cluster pVD4 (novE under control of its 
genuine promoter) 
     38.1             191 
S.coelicolor(nov-VD2) ΔnovE pVD1 (novG under control of 
the constitutive ermE*  
promoter) 
     59.8             299       
S.coelicolor(nov-VD2) 
 
ΔnovE pAE8 (novG under control of its 
genuine promoter) 
     34.6             173 
S.coelicolor(nov-AE10) ΔnovG pWHM3 (empty vector)       0.4                  2 
S.coelicolor(nov-AE10) ΔnovG pVD4 (novE under control of its 
genuine promoter) 
      2.4                12 
S.coelicolor(nov-AE10) ΔnovG pAE8 (novG under control of its 
genuine promoter) 
       16                80 
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III.1.2. Overexpression of novE in S. coelicolor M512 (nov-BG1) results in 
overproduction of novobiocin 
 
Overexpression of pathway-specific activators can result in overproduction of the 
respective antibiotic (Stutzman-Engwall et al., 1992). Therefore, the novE expression 
plasmid pVD4 was introduced into S. coelicolor M512 (nov-BG1) by protoplast 
transformation. As presented in Table III.1, transformation with pVD4 led to a 1.9-fold 
increase in novobiocin production in comparison to S. coelicolor M512 (nov-BG1) 
carrying only the empty vector pWHM3.  
 
III.1.3. Complementation of the novE mutation by novG under control of the 
constitutive ermE* promoter 
 
The results mentioned above are consistent with a role of novE as a positive 
regulator of novobiocin biosynthesis. Previous results (Eustáquio et al., 2005b) had 
proven that also novG acts as a positive regulator of the biosynthesis of this antibiotic. 
This raised the question whether the two regulators, novE and novG, act in parallel or 
in a cascade-like mechanism. In order to investigate the interplay between novE and 
novG, a novG expression construct was introduced into the ΔnovE strain. 
 
Therefore, novG was placed under control of the constitutive ermE* promoter in the 
expression vector pUWL201 (Doumith et al., 2000), resulting in pVD1. This plasmid 
was transformed into the ΔnovE strain S. coelicolor M512 (nov-VD2) resulting in a 
dramatic increase of novobiocin production (Table III.1). The fact that novobiocin 
production in a ΔnovE strain can be restored by overexpression of the regulatory 
gene novG strongly indicates that novE has a regulatory rather than catalytic function. 
 
III.1.4. Electrophoretic mobility shift assays (EMSA) 
 
A plausible hypothesis to explain the observation described above would be that 
novE is a positive regulator of novG, which in turn is a positive regulator of the 
expression of the biosynthetic enzymes of novobiocin. NovG has been shown to bind 
to the DNA region between novG and novH (Eustáquio et al., 2005b). Using gel-
mobility shift assays, Alessandra Eustáquio could readily reproduce this result 
(Fig.III.2a). Subsequently, the coding sequence of novE was amplified by PCR and 
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cloned into the expression vector pRSET B. Using the resulting plasmid pAE18, 
NovE was expressed in E. coli as soluble, N-terminally His6 tagged protein and 
purified by Ni2+ affinity chromatography. This protein was used in band shift assays 
with three different DNA fragments located upstream of the novG start codon. 
However, no mobility shift was observed. Likewise, no binding could be shown with a 
DNA fragment located upstream of novF, and neither with fragments upstream of 
novE which were tested in order to check for a possible autoregulation of novE 
(Fig.III.2b). These results do not support the hypothesis that novE acts by direct DNA 
binding in the novEFG region, and this is in accordance with the fact that 
bioinformatic analysis does not show any DNA binding motif in the predicted amino 
acid sequence of NovE. The EMSA mentioned above were carried out by Alessandra 
Eustáquio. 
 
 
Fig. III.2: Electrophoretic mobility shift assays with fragments from the novobiocin 
biosynthetic gene cluster. See next page for details. 
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Autoradiogram of gel mobility-shift assays using (a) purified His6-tagged NovG; (b) purified 
His6-tagged NovE. Analysis of DNA-binding activity was carried out as described in (Dangel 
et al., 2008), using approximately 4 ng of the indicated DIG-end-labelled fragment and either 
no protein (-) or 1.5 µg of purified His6-tagged NovG or  3 µg of purified His6-tagged NovE 
protein (+). Above each autoradiogram a map is given showing the location of the DNA 
fragments used (out of scale; the intergenic regions are oversized in comparison to the 
coding sequences). The fragments were obtained by digestion of appropriate plasmids or by 
PCR amplification. For fragments obtained by digestion, the restriction sites are indicated: E, 
EcoRI; P, PvuI; S, SalI; A, AvaI. 
 
III.1.5. Complementation of the novE mutation by novG under control of its 
own promoter 
 
The failure to show binding of NovE to the novG promoter region questioned the 
hypothesis that novE acts as positive regulator of novG transcription. Therefore, 
plasmid pAE8 (Eustáquio et al., 2005b) which contains the structural gene novG 
together with its genuine promoter region in the promoterless E. coli/Streptomyces 
shuttle vector pWHM3 (Vara et al., 1989) was used to complement the ΔnovE strain 
described above. Indeed, complementation was readily achieved with this construct 
(Table III.1). This proved that novG-expression from its own promoter can occur in 
the absence of NovE. 
 
III.1.6. Complementation of the novG mutation by novE 
 
A heterologous expression strain carrying a novG deficient novobiocin cluster, i.e.  
S. coelicolor M512 (nov-AE10) (Eustáquio et al., 2005b), produced only 2 % of the 
novobiocin amount found in the strains carrying the intact cluster (Table III.1). When 
this strain was transformed with plasmid pVD4, carrying novE under control of its own 
promoter, production levels increased approximately 6-fold (Table III.1), but did not 
reach the original production levels of the strains carrying the intact cluster. In 
contrast, complementation of the novG-defective strain with an intact copy of novG 
under control of its own promoter (pAE8) restored most of the original production 
(Table III.1). Therefore, novG is able to fully complement a novE defect but novE can 
only partly complement a novG defect. 
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III.1.7. RT-PCR experiments 
 
In order to investigate whether novG transcription depends on the presence of NovE, 
and whether novE transcription depends on the presence of NovG, RT-PCR 
experiments were carried out in the strain carrying the complete cluster, as well as in 
the strains lacking the novE or the novG gene, respectively (Fig. III.3). The outcome 
of these experiments showed that at least some novG transcription takes place in the 
absence of NovE, and likewise that novE transcription occurs in the absence of NovG.  
 
 
 
Fig. III.3: RT-PCR analysis. RT-PCR results of novE and novG transcription in 
Streptomyces coelicolor(nov-BG1) containing the entire novobiocin biosynthetic gene cluster, 
in the novE-defective strain Streptomyces coelicolor(nov-VD2) and in the novG-defective 
strain Streptomyces coelicolor(nov-AE10) (Eustáquio et al., 2005b)); 1-5 = different times of 
cultivation (1 = 22 hours, 2 = 30 hours, 3 = 44 hours, 4 = 77 hours, 5 = 94 hours); hrdB = 
house-keeping gene encoding for the sigma factor of the DNA-dependent RNA-polymerase; 
novE and novG = putative regulatory genes. 
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III.2. Investigations on the genetic organization and transcriptional 
regulation of the novobiocin biosynthetic gene cluster 
 
III.2.1. Sequence analysis of the novobiocin biosynthetic gene cluster 
 
The novobiocin biosynthetic gene cluster spans 23.4 kb and comprises 20 coding 
sequences (Li & Heide, 2004; Li & Heide, 2006). The genes novHIJKLM, separated 
by very short intergenic regions (<19 bp), are responsible for the synthesis and the 
linkage of the aminocoumarin moiety (Fig. I.3). novQR are responsible for the 
generation of the prenylated 4-hydroxybenzoate moiety, and novSTUVW for the 
generation of the deoxysugar. The coding sequences for novQ and novR, as well as 
of novS and of novV and novW, overlap, suggesting a translational coupling of these 
genes. novN, novO and novP are responsible for tailoring reactions, i.e. the 
carbamoylation and methylation of the novobiocin skeleton (Fig. I.3). novF is 
probably responsible for the availability of 4-hydroxyphenylpyruvate, a precursor of 
both aromatic moieties of novobiocin (Fig. I.3). gyrBR codes for a resistance gene, 
and novE and novG for putative regulators of novobiocin biosynthesis (see 
introduction and III.1.). Large intergenic regions, suggestive of the presence of 
promoters, are found within the cluster, i.e. upstream of novE (180 bp intergenic 
region), novG (105 bp), novH (195 bp), novO (230 bp) and gyrBR (376 bp). 
 
For three of these regions, direct or indirect experimental evidence has confirmed 
their promoter activity, i.e. for the regions upstream novE (Dangel et al., 2008), novH 
(Eustáquio et al., 2005b) and gyrBR (Thiara & Cundliffe, 1989). In contrast to the 
streptomycin cluster, which contains four binding-sites of the positive regulator 
protein StrR, the novobiocin cluster contains only a single binding-site for the StrR-
ortholog NovG. This binding-site is situated upstream of novH (Eustáquio et al., 
2005b). Both, bioinformatic sequence analysis and electrophoretic mobility shift 
assays confirmed that no NovG binding-site is situated in the large intergenic region 
upstream of novO (Alessandra Eustáquio´s thesis). 
 
Therefore, all 16 genes from novH to novW, which are arranged in the same 
orientation and code for all enzymes of novobiocin biosynthesis from 4 HPP (Fig. I.3), 
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may be transcribed as a single operon under control of the promoter upstream of 
novH. This promoter is probably regulated by the DNA-binding protein NovG. 
 
III.2.2. Insertion of transcriptional terminators into the novobiocin 
biosynthetic gene cluster 
 
A convenient method for the mapping of transcription units is the use of Ω (omega) 
interposon, i.e. a DNA fragment containing an antibiotic resistance marker flanked by 
short inverted repeats which contain termination signals for transcription (Prentki & 
Krisch, 1984). 
 
In these studies the Ωaac cassette (Blondelet-Rouault et al., 1997) was used which 
contains the apramycin resistance gene aacC4, selectable both in E. coli and in 
Streptomyces. While previous studies used conventional cloning techniques to 
introduce their cassette into the transcription unit of interest (Raynal et al., 2006), in 
these studies the much more versatile λ RED-mediated recombination technique 
(Gust et al., 2004) was used to insert the 1.8 kb Ωaac cassette into the coding 
sequence of the genes novE, novF, novG, novH, novO and novS. In each case, the 
cassette was inserted between nucleotides 3 and 7 of the coding sequence of the 
gene, i.e. replacing the second codon of the coding sequence. For this purpose, the 
Ωaac cassette was amplified with primers containing 39 bp homolog extensions, 
identical to the sequences upstream and downstream of the second codon of the 
gene of interest. The PCR products were used for λ RED-mediated recombination in 
E. coli, using cosmid nov-BG1 as target (Eustáquio et al., 2005a). This cosmid 
contains the complete novobiocin cluster, as well as the integration functions of the 
phage ΦC31. The resulting cosmids with the inserted Ωaac cassettes were 
integrated into the genome of Streptomyces coelicolor M512 as described previously 
(Eustáquio et al., 2005a). Southern blotting confirmed that in all integration mutants 
the entire cosmid had integrated site-specifically into the ΦC31 attachment site of the 
genomic DNA (data presented in Johannes Härle´s diploma thesis). 
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III.2.3. Identification of promoter regions by reverse transcriptase PCR-
analysis of termination mutants  
 
As shown previously, heterologous expression of the intact novobiocin cluster in S. 
coelicolor M512 leads to the production of novobiocin, in amounts similar to those 
formed by the wild-type novobiocin producer strain (Eustáquio et al., 2005a). 
Correspondingly, reverse transcriptase PCR (RT-PCR) experiments now revealed 
the presence of transcripts for all genes of the novobiocin gene cluster when the 
strain was cultivated in novobiocin production medium (Fig. III.4a). Controls without 
the preceding reverse transcriptase reaction confirmed that the detected signals were 
due to cDNA rather than to contamination with genomic DNA. 
 
Insertion of the Ωaac cassette into a transcription unit leads to termination of mRNA 
synthesis, therefore to a lack of RT-PCR signals for the genes downstream of the 
inserted cassette. Transcription is re-initiated at the next active promoter sequence 
downstream of the Ωaac insertion. As shown in Fig. III.4b, c and d, insertion of the 
Ωaac cassette into novE, novF and novG led, as expected, to a complete 
abolishment of the transcription of the affected genes. In all three cases, however, 
transcripts of the adjacent gene, i.e. novF, novG and novH, repectively, were 
detectable, indicating the presence of promoter regions upstream of these genes. In 
contrast, insertion of Ωaac into novH led to a complete abolishment of the 
transcription of novHIJKLMN, indicating that all of these genes form a single 
transcription unit (Fig. III.4e). Transcripts were detected, however, for novO and the 
genes downstream thereof, indicating the presence of a promoter region upstream of 
novO. 
 
Consequently, three additional mutant strains have been generated, carrying Ωaac 
cassettes in novO, novP and novQ using the same method as described above. In 
the first two cases, transcripts of the adjacent genes, i.e. novP and novQ were 
detected (Fig. III.4f and g), indicating promoter sequences located upstream of these 
genes. In the strain carrying Ωaac cassette in novQ, however, transcription of the 
following genes was completely abolished, indicating that these genes form a 
transcription unit (Fig. III.4h). This was confirmed by the results from the strain 
carrying Ωaac in novS, showing complete abolishment of the transcription of 
novSTUVW (Fig. III.4i). 
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Therefore, our experiments confirmed the previously supplied indirect evidence that a 
promoter region is located upstream of novH, and additionally showed that promoter 
regions appear to be localised upstream of novF, novG, novO, novP and novQ. 
Experimental evidence for the promoter activity of the DNA region upstream of the 
putative regulator novE and the resistance gene gyrBR has been published previously 
(Dangel et al., 2008; Thiara & Cundliffe, 1989). Therefore, at least eight promoter 
regions are present within the novobiocin cluster (Fig. III.4k).  
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Fig. III.4 See next page for details. 
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(a-i) Schematic presentation of constructs nov-BG1, nov-JH1 to nov-JH6, nov-JH10 and nov-
JH12 including RT-PCR results (the practical part of these investigations was carried out in 
cooperation with Johannes Härle as diploma student; for details see Johannes Härle´s 
diploma thesis). (k) Transcriptional organisation of the novobiocin biosynthetic gene cluster 
including gyrBR. 
 
III.2.4. Real-time PCR investigations of the transcriptional regulation of the 
novobiocin cluster by novE and novG 
 
In order to investigate the influence of novE and novG on the transcription of the 
genes of the novobiocin cluster, quantitative RT-PCR (qRT-PCR) experiments using 
the LightCycler® method were carried out. Suitable primer pairs were chosen for each 
of the eight genes located downstream of putative promoter sequences within the 
novobiocin cluster, i.e. novE, novF, novG, novH, novO, novP, novQ and gyrBR. 
Reaction conditions, i.e. annealing temperature and MgCl2 concentrations, were 
optimized for each primer pair until a linear relationship between the logarithm of the 
mRNA concentration and the cycle number was obtained over a concentration range 
of at least two orders of magnitude. 
 
The respective reaction conditions are described in the experimental, and the PCR 
primers are shown in Table II.17. For novE, novG and novP the primers designed for 
the reverse transcriptase PCR could also be used for qRT-PCR. For novF, novH, 
novO and novQ, however, new primers had to be designed for quantitative mRNA 
determination. 10 ng of total RNA were used for each LightCycler® reaction. The 
hrdB transcript, coding for the principle sigma-like transcription factor of 
Streptomyces coelicolor, was used as internal standard and the number of transcripts 
for each sample was normalized to hrdB. 
 
qRT-PCR analysis was then carried out for a strain carrying the intact novobiocin 
cluster, as well as for strains carrying clusters in which either the gene novE or the 
gene novG had been inactivated by an in-frame deletion within the coding sequence. 
The generation of these three strains and the use of Streptomyces coelicolor M512 
as host for the heterologous expression of the clusters has been described previously 
(Dangel et al., 2008; Eustáquio et al., 2005a; Eustáquio et al., 2005b). 
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Cultivation of these three strains in the chemically defined novobiocin production 
medium was carried out in 24-square deepwell plates (Duetz et al., 2000) which 
allows much more reproducible cell growth and novobiocin production rates than 
conventional Erlenmeyer flask cultivations (Stefanie Siebenberg´s thesis). 
 
First, the time course of novobiocin production in this culture system was determined. 
In accordance with previous results (Stefanie Siebenberg´s thesis) only traces of 
novobiocin production were detected within the first 48 hours after inoculation, while 
the highest novobiocin production rate was observed between 72 and 96 hours after 
inoculation (Fig. III.5a). 
 
In contrast, dry cell weight increases between 24 and 72 hours after inoculation 
(Stefanie Siebenberg´s thesis). Identical to the observation from the genuine 
producer strain that novobiocin production starts at the transition from growth phase 
to stationary phase (Kominek, 1972).  
 
As may be expected, the highest amounts of transcripts for the novobiocin 
biosynthetic genes novH, novO, novP and novQ were detected immediately before 
the onset of novobiocin production, i.e. 48 hours after inoculation (Fig. III.5, e-h). All 
transcripts were still clearly detectable after 72 and 96 hours, i.e. well into stationary 
phase. Expression of all four genes was perfectly synchronous, which is in 
accordance with the hypothesis stated above that all these genes may be transcribed 
as a single operon. For the genes coding for enzymes of novobiocin biosynthesis, i.e. 
novH and novOPQ, hardly any transcripts were found at 32 hours after inoculation. In 
contrast, transcripts for the two putative regulators novE and novG could clearly be 
detected at this time point, indicating that the expression of the regulatory genes may 
precede the expression of the biosynthetic enzymes (Fig. III.5,b and d). Maximal 
transcripts amount of novE and novG were found 48 hours after inoculation. 
 
The resistance gene gyrBR showed a low level of transcription even at 24 hours after 
inoculation. A first maximum of gyrBR transcripts was detected after 48 hours, i.e. 
synchronous to the expression of novH and novOPQ. It is tempting to speculate that 
gyrBR may be co-transcribed together with these genes. In contrast to novH and 
novOPQ, however, the amount of transcripts for gyrBR increases again after 72 hours, 
i.e. when novobiocin concentration is increasing. This is in perfect accordance with 
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the results of (Thiara & Cundliffe, 1989), who cloned the promoter region of gyrBR 
into a promoter probe vector and showed (by expression in Streptomyces lividans 
TK24) that the promoter was induced by cultivation in the presence of novobiocin. 
Since cultivation in the presence of ciprofloxacin, a gyrase-inhibitor interacting with 
the A subunit of this enzyme, had the same inducing effect, Thiara and Cundliffe 
suggested that the induction is not directly mediated by novobiocin but by the change 
of superhelical density of chromosomal DNA, caused via the gyrase inhibition 
excerted by novobiocin or ciprofloxacin. 
 
In contrast to the strain with the intact cluster, the two strains with in-frame deletions 
in the putative regulators novE and novG showed only very low novobiocin 
production (Fig. III.5a). Seven days after inoculation, the strain with the intact cluster 
had accumulated 45 mg/l novobiocin, whereas the ΔnovE and ΔnovG strain had 
produced less than 0.4 mg/l. 
 
As immediately obvious from Fig. III.5e-h, the amounts of transcripts for the 
novobiocin biosynthetic genes novH and novOPQ were dramatically reduced in the 
ΔnovE and ΔnovG strains in comparison to the strain with the intact cluster, providing 
for the first time, direct evidence that novE and novG act as transcriptional regulators 
of novobiocin biosynthesis. 
 
Notably, also novG transcription was strongly reduced in the ΔnovE strain: at 48 
hours after inoculation, the amount of transcripts was only 5 % of that observed in the 
strain with the intact cluster (Fig. III.5d). This suggests that novG expression is 
largely, though not entirely dependent on the presence of novE. In contrast, novE 
expression was still high in the ΔnovG strain (Fig. III.5b), suggesting that novE 
expression is not dependent on novG. 
 
The resistance gene gyrBR shows low basal transcription during the growth phase of 
both, the ΔnovE and the ΔnovG strain, suggesting a low constitutive expression from 
the gyrBR promoter. An alternative explanation is that the basal transcription rate 
observed for gyrBR results in fact from the highly similar constitutively expressed 
gene gyrB (=SCO3874) of the host strain S. coelicolor. This gene has 82% identity 
with gyrBR on the nucleotide level, and the priming-site for the forward and reverse 
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primer for gyrBR can also be found in this gene, although with five and two 
mismatches, respectively. 
 
The predicted gene product of novF shows high sequence similarity to prephenate 
dehydrogenases and is therefore expected to supply 4-hydroxyphenylpyruvate (4-
HPP), the common precursor of both, the prenylated 4-hydroxybenzoate moiety and 
the aminocoumarin moiety of novobiocin (Fig. I.3). Expression of novF is detectable 
at 32 hours after inoculation (Fig. III.5c), i.e. earlier than the expression of the 
biosynthetic genes novH and novOPQ. This may ensure the availability of the 
precursor 4-HPP just before the novobiocion biosynthesis is initiated. Transcription of 
novF is remarkably similar to that of novE in the strain with the intact cluster and in 
the ΔnovG strain (Fig. III.5c), which indicates either a close co-regulation or even a 
co-transcription of both genes. 
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Fig. III.5: (a) Production curves and (b-i) results of qRT-PCR experiments for Streptomyces 
coelicolor M512 (nov-BG1) containing the entire novobiocin biosynthetic gene cluster, 
Streptomyces coelicolor M512 (nov-VD2) containing the novE-defective cluster (Dangel et al., 
2008) and Streptomyces coelicolor(nov-AE10) containing the novG-defective cluster 
(Eustáquio et al., 2005b). 
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III.2.5. Contribution of the promoter regions upstream of novO, novP and 
novQ to the transcription of the novobiocin cluster 
 
Insertion of the Ωaac cassette into novH led to the complete termination of the 
transcription of novHIJKLMN (see above). Consistently, the strain carrying this 
insertion (hereafter called ΩnovH strain) did not produce any detectable amounts of 
novobiocin (<0.2 mg/l), while a strain carrying the intact cluster produced 51 mg/l 
novobiocin. Notably, however, the ΩnovH strain did also produce detectable amounts 
of the prenylated 4-hydroxybenzoate moiety (0.3 mg/l). In contrast, a clorobiocin 
producer strain in which the gene cloI (orthologues to novI) had been inactivated by 
in-frame deletion produced 3.75 mg/l of the prenylated 4-hydroxybenzoate moiety 
(Pojer et al., 2003). 
 
This suggested that in the ΩnovH strain only small amounts of novQ and novR 
transcripts (which direct the biosynthesis of prenylated 4-hydroxbenzoate) are formed. 
This was confirmed by qRT-PCR experiments, composing the expression rate of 
novG, novH, novP and novQ in S. coelicolor M512 (nov-BG1) (carrying the intact 
cluster) and S. coelicolor M512 (nov-JH4) (carrying the ΩnovH cluster) (Fig. III.6). In 
the latter strain the transcription of novH was reduced to <1 % in comparison to the 
former strain, but also the transcription of novP and novQ was reduced to 3% in 
comparison to the strain with the intact cluster (Fig. III.6). This can be explained by 
the hypothesis that transcription of novO, novP and novQ (and of the genes located 
downstream thereof) is mainly controlled by the novH promoter initiating a large 
transcript from novH to novW, while the promoter regions upstream of novO, novP 
and novQ have only minor relevance for the amount of transcripts formed. This is 
consistent with the results from bioinformatic analysis which showed no NovG 
binding-site in the novOPQ region. 
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Fig. III.6: Results of qRT-PCR experiments for Streptomyces coelicolor M512 (nov-BG1) 
containing the entire novobiocin biosynthetic gene cluster and Streptomyces coelicolor M512 
(nov-JH4) containing the ΩnovH-cluster. 
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III.2.6. A high novobiocin production is achieved by an optimized novG 
expression vector 
 
The results described above suggest that control of transcription from the novH 
promoter is the central mechanism for the regulation of novobiocin biosynthesis. It is 
tempting to investigate whether this knowledge can be used to further increase 
novobiocin yields. 
 
In a previous study (Eustáquio et al., 2005b) novobiocin production could be restored 
in a novG-defective heterologous expression strain by complementation with the 
multicopy plasmid pAE8, containing an intact copy of novG. Notably, in a strain 
containing an intact novobiocin cluster, i.e. in S. coelicolor (nov-BG1), pAE8 caused a 
2.7-fold overproduction of novobiocin. In the present study, this result could be 
reproduced, obtaining 2.9-fold overproduction by pAE8 in comparison to the empty 
vector control. 
 
NovG has been identified as a DNA binding protein. Both, electrophoretic mobility 
shift assays and bioinformatic sequence analysis have identified the NovG binding-
site, a palindromic structure beginning 2 bp downstream of the novG stop codon, i.e. 
194 bp upstream of novH start codon (Fig. III.7). Due to the recognition that pAE8, 
the first plasmid for novG overexpression, contained 135 bp of the intergenic region 
downstream of novG, i.e. pAE8 included the NovG binding-site (Fig. III.7), it was 
tempting to speculate that pAE8 may not be an optimal construct for the stimulation 
of novobiocin production, as the produced NovG protein may bind to the NovG 
binding-site in pAE8, which is present in many copies in the cell, leaving only a 
fraction of the produced NovG available for binding to the site in the novobiocin 
cluster which had been integrated into the genome of the heterologous host. 
Therefore, a new novG expression plasmid was constructed by Alessandra 
Eustáquio, named pAE12, which contained just 1 bp of the intergenic region 
downstream of novG, and therefore did not contain the NovG binding-site (Fig. III.7). 
Otherwise, this plasmid was identical to pAE8. Transformation of this plasmid into a 
heterologous expression strain carrying the intact novobiocin cluster resulted in 8.4-
fold overproduction of novobiocin compared to the empty vector control. Therefore, 
transformation with pAE12 turned out to be the most effective method identified so far 
in order to increase novobiocin production in a heterologous producer strain. 
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Fig. III.7: Inserts of the novG overexpression plasmid pAE8 and pAE12. Both inserts were 
cloned into the promoterless pWHM3 vector. (Generation of pAE8 and pAE12 were carried 
out by Alessandra Eustáquio). 
 III. RESULTS 81 
III.3. Regulation of novobiocin production by insertion of a 
tetracycline-controllable promoter 830 (tcp830) 
 
As presented above, initiation of transcription from the promoter situated upstream of 
novH, i.e. in the intergenic region novG_novH, is the most important event for the 
regulation of novobiocin biosynthesis in the heterologous host. In accordance with 
this finding, the introduction of a strong inducible promoter upstream of novH may, in 
principle, result in high production and, therefore, may represent a promising strategy 
to uncouple novobiocin production from its natural regulation cascade. 
 
Till now, the thiostrepton inducible promoter ptipA (Murakami et al., 1989) represents 
the most widely used inducible promoter for regulating gene expression in 
Streptomyces spp. providing reliable and controllable gene expression under 
different circumstances. However, thiostrepton is known to induce a regulon of 
proteins, and to depend on the presence of an activator, TipAL, and a resistance 
gene, tsr (Ali et al., 2002; Murakami et al., 1989; Weaden & Dyson, 1998). Therefore, 
the tetracycline controllable promoter 830 (tcp830) represents an alternative valuable 
inducible promoter due to its activity in a wide range of natural tetracycline resistant 
Streptomyces species (Rodriguez-Garcia et al., 2005). Furthermore, using the luxAB 
genes expressing luciferase as a reporter system, tcp830 has been shown to reach 
induction factors of up to 270. 
 
The strategy to uncouple novobiocin biosynthesis from its natural regulation cascade, 
used in this study, was the replacement, not only of the promoter region upstream of 
novH (Fig. III.4k) but additionally of the entire novEFG region, by the tetracycline 
controllable promoter830 (tcp830). 
 
III.3.1. Generation of a novE-novG-double defective mutant 
 
Since the strategy to uncouple novobiocin production from its origin regulation circuit 
used in this study includes the deletion of both pathway-specific positive regulators 
novE and novG, a Streptomyces coelicolor M512 strain with a ΔnovEΔnovG-cluster 
was generated in order to show the effect of inactivation of novE and novG on 
novobiocin production. Therefore, novE was deleted in cosmid nov-AE10 (ΔnovG), 
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followed by integration of the resulting ΔnovEΔnovG-cosmid (named nov-VD4) into 
S.coelicolor M512.  
 
For this purpose, novE was replaced in cosmid nov-AE10 (ΔnovG) by an apramycin 
resistance cassette flanked by FRT (FLP-recognition target) sites via λ RED-
mediated recombination (Datsenko & Wanner, 2000; Gust et al., 2003), resulting in 
nov-VD3. This cassette was excised using FLP-recombinase leaving an in-frame 
“scar” of 81 nucleotides between the start and stop codon of novE. The resulting 
ΔnovEΔnovG-cosmid (named nov-VD4) (Fig. III.8) was subsequently introduced into 
S.coelicolor M512 by protoplast transformation, and its site-specific integration into 
the genome was confirmed by Southern blot analysis. HPLC analysis showed that 
inactivation of both pathway-specific regulators, resulted in an almost loss of 
novobiocin production, i.e. in non detectabable amounts. Notably, previous 
investigations showed that Streptomyces coelicolor M512 strains containing either a 
novE- or a novG-defective novobiocin biosynthetic gene cluster still produced 
novobiocin in detectable, but dramatic reduced amounts (0.7% - 2%) in comparison 
to strains harboring the entire cluster (Table III.1). 
 
Subsequently, novE together with its own putative promoter, i.e. including 599 bp 
upstream of the start codon of novE, was cloned into pAE12, that contains novG 
together with its own putative promoter, i.e. 336 bp upstream of the start codon of 
novG in the promoterless shuttle vector pWHM3, resulting in pVD10. The introduction 
of pVD10 into S.coelicolor M512 (ΔnovEΔnovG) led to restoration of novobiocin 
production in the resulting transformants (120 % in comparision to S. coelicolor (nov-
BG1, containing the entire novobiocin cluster) and therefore confirmed that the 
almost loss of novobiocin production in Streptomyces coelicolor M512 (ΔnovEΔnovG) 
was indeed caused by inactivation of both positive regulators novE and novG. 
 
III.3.2. Uncoupling of novobiocin production from its natural regulation 
cascade 
 
In order to increase novobiocin production the apra-tcp830 cassette from pMS80, 
containing the tetracycline-controllable promoter 830 (tcp830) and an apramycin 
resistance gene, flanked by FRT-sites (Rodriguez-Garcia et al., 2005), was 
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introduced into cosmid nov-BG1 in exchange with the region from novD stop codon 
to novH start codon via λ RED-mediated recombination. The resulting cosmid was 
named nov-VD6 (Fig. III.8). Due to the risk that the effect of tcp830 could not be 
sufficient to ensure high transcription of all genes from novH to novW, comprising 18 
kb, a second tcp830 cassette was introduced into the novobiocin biosynthetic gene 
cluster in exchange with the intergenic region novP_novQ. For this purpose, the 
apramycin resistance gene in nov-VD6 was firstly deleted by expression of the FLP-
recombinase, leaving a “scar” of 81 nucleotides upstream of tcp830. The resulting 
cosmid was named nov-VD7 (Fig. III.8). The following attempt to introduce a second 
apra-tcp830 cassette into nov-VD7 in exchange with the intergenic region 
novP_novQ, by the repeated use of λ RED-mediated recombination did not succeed 
due to sequence homologies between the newly generated PCR-product and the 
already existing tcp830 sequence situated upstream of novH. Instead, a complete 
loss of the region from novH start codon to novQ start codon was observed. For this 
reason, λ RED-mediated recombination was modified as follows: the first step was 
the introduction of the apra-tcp830 cassette from pMS80 into cosmid nov-BG1 in 
exchange with the intergenic region novP_novQ via λ RED-mediated recombination, 
resulting in cosmid nov-VD8 (Fig. III.8). After digestion of nov-VD8 with KpnI and 
SacII, the obtained 4551 bp restriction fragment, comprising the region from 671 bp 
upstream of novN stop codon to 525 bp downstream of novQ start codon, including 
the apra-tcp830 cassette within the intergenic region novP_novQ, was successfully 
introduced into cosmid nov-VD7 via λ RED-mediated recombination, resulting in 
cosmid nov-VD9 (Fig. III.8). No illigitime recombination was observed this time due to 
the long flanking DNA sequences for homologous recombination by using the 4551 
bp restriction fragment instead of the 1596 bp PCR product. Subsequently, the 
obtained cosmids nov-VD7, nov-VD8 and nov-VD9 were introduced into 
Streptomyces coelicolor M512 by protoplast transformation, followed by confirmation 
of their site-specific integration into the genome by southern blot analysis. 
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Fig.III.8: Schematic presentation of constructs nov-BG1, nov-VD4, nov-VD6, nov-VD7, nov-
VD8 and nov-VD9. 
 
III.3.3. Optimization of induction-conditions for tcp830 towards maximal 
novobiocin production 
 
Investigations on the determination of optimal aTc (anhydro-Tetracycline)-
concentration and time for induction of tcp830 towards maximal novobiocin 
production were carried out using one transformand of S.coelicolor M512 (nov-VD9) 
and S.coelicolor M512 (nov-BG1), harboring the entire novobiocin biosynthetic gene 
cluster, as a control. 
 
For this purpose, cultivation was carried out in absence and after addition of 0.25, 0.5, 
1, 2, 4, 8 or 16 µg/ml aTc at inoculation time. HPLC-analysis confirmed that 
S.coelicolor M512 (nov-VD9) produced novobiocin even in absence of aTc, but only 
in reduced amounts (24%) in comparison to S.coelicolor M512 (nov-BG1) harboring 
the entire novobiocin biosynthetic gene cluster. In contrast, the induction of tcp830 in 
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S.coelicolor M512 (nov-VD9) by addition of 0.25 to 2 µg/ml aTc resulted in a dramatic 
increase of novobicin production (20-fold), representing not only restoration in 
comparison to S.coelicolor M512 (ΔnovEΔnovG), but additionally an up to 4.9-fold 
overproduction of novobiocin in comparison to S.coelicolor M512 (nov-BG1), 
harboring the entire novobiocin biosynthetic gene cluster under its natural regulation 
(Fig. III.9a). In contrast, addition of 0.25 to 2 µg/ml aTc did not significantly influenced 
novobiocin production in S.coelicolor M512 (nov-BG1) (Fig. III.9a). Further 
investigations on dry weight showed, that addition of aTc in concentrations from 0.25 
to 2 µg/ml exhibits almost no effect on S. coelicolor M512 (nov-BG1) and only small 
positive effects on S.coelicolor M512 (nov-VD9) (Fig. III.9b). In accordance to these 
results, the addition of 1 µg/ml aTc for induction of tcp830 was determined to achieve 
maximal novobiocin production. 
 
Subsequently, the optimal time for induction of tcp830 was investigated by addition of 
1 µg/ml aTc at inoculation-time and after 6, 12, 24, 36, 48 or 72 hours of cultivation. 
HPLC-analysis showed that modification of induction-time from inoculation-time did 
not lead to a further increase of novobiocin production (data not shown). Therefore, 
addition of 1 µg/ml aTc at inoculation time was used for further investigations. 
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Fig. III.9 (a) Novobiocin production and (b) dry weight of S.coelicolor M512 (nov-BG1), 
containing the entire novobiocin cluster and S.coelicolor M512 (nov-VD9), containing nov-
BG1 with the region from novD stop codon to novH start codon and novP stop codon to 
novQ start codon replaced with (apra-)tcp830 in absence and after addition of 0.25, 0.5, 1, 2, 
4, 8 and 16 mg/l aTc at inoculation time. 
 
III.3.4. Quantitative comparison of novobiocin production under natural 
promotor and inducible promotor control 
 
For quantitative analysis of novobiocin production, three independent transformants 
of S.coelicolor M512 (nov-VD7), S.coelicolor M512 (nov-VD8), S.coelicolor M512 
(nov-VD9) and S. coeliocolor M512 (nov-BG1) as a control were cultivated in 
absence and after addition of 1 µg/ml aTc at inoculation-time. The following HPLC-
analysis of secondary metabolite production showed, that all mutants harboring 
tcp830, produced novobiocin even in absence of aTc, but only in reduced amounts 
(12 to 48%) in comparison to S.coelicolor M512 (nov-BG1) (data not shown). 
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However, the induction of tcp830 led to a dramatic increase of novobiocin production 
in all three mutants, resulting in overproduction of novobiocin in comparison to 
S.coelicolor M512 (nov-BG1), i.e. 1.5-fold for S.coelicolor M512 (nov-VD8), 1.6-fold 
for S.coelicolor M512 (nov-VD9) and 2-fold for S.coelicolor M512 (nov-VD7) (Fig. 
III.10). In accordance with these results, introduction of tcp830 upstream of novH, i.e. 
in S.coelicolor M512 (nov-VD7), has been confirmed of being sufficient not only to 
fully complement the novEFG-deletion, but moreover to overexpress the entire 
novobiocin biosynthetic gene cluster, resulting in overproduction of novobiocin. 
Quantitative HPLC-analysis of Ring A formation showed, that S.coelicolor M512 (nov-
VD7) and S.coelicolor M512 (nov-VD9) did not produce any detectable amounts of 
Ring A. In contrast, the introduction of tcp830 in exchange with the intergenic region 
novP_novQ, i.e. in S.coelicolor M512 (nov-VD8), resulted in a 4.2-fold overproduction 
of Ring A in comparison to S.coelicolor M512 (nov-BG1) (Fig. III.10). This 
observation is in accordance with the localization of tcp830 in cosmid nov-VD8 (Fig. 
III.8), i.e. upstream of novQ, that in addition to novR encodes enzymes involved in 
Ring A formation (Li & Heide, 2004). 
 
Fig. III.10: See next page for details. 
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Novobiocin production (black bars) of S.coelicolor M512 (nov-BG1) containing the entire 
novobiocin biosynthetic gene cluster, S.coelicolor M512 (nov-VD7) containing nov-BG1 with 
the region novD stop codon to novH start codon replaced by tcp830, S.coelicolor M512 (nov-
VD8) containing nov-BG1 with the region novP stop codon to novQ start codon replaced by 
apra-tcp830 and S.coelicolor M512 (nov-VD9) containing nov-VD7 with the region novP stop 
codon to novQ start codon replaced by apra-tcp830 and Ring A formation (white bars) of 
S.coelicolor M512 (nov-BG1) and S.coelicolor M512 (nov-VD8). Values are means of at least 
three independent mutants and two independent cultivations 
 
 IV. DISCUSSION 89 
IV. DISCUSSION 
IV.1. Investigations on the role of novE in the regulation of 
novobiocin biosynthesis and its interplay with novG 
 
The biosynthetic gene cluster of the aminocoumarin antibiotics novobiocin, 
clorobiocin and coumermycin A1 each contain two putative regulatory genes with high 
similarity within the clusters, i.e. novG/cloG/couG and novE/cloE/couE. The function 
of NovG as a DNA binding protein and positive regulator of novobiocin biosynthesis 
has been established (Eustáquio et al., 2005b). This study investigated the function 
of novE.  
 
The observations that the inactivation of novE led to a strong reduction but not to a 
complete abolishment of novobiocin production, that the overexpression of novE led 
to an increase of novobiocin production and that the novE defect could be 
complemented by an overexpression of the regulatory gene novG supported the 
hypothesis that novE had a regulatory rather than a catalytic function. 
 
It was tempting to speculate that NovE may regulate the transcription of novG. 
However, RT-PCR experiments suggested that at least some novG transcription can 
occur in the absence of NovE, and that novE transcription can occur in the absence 
of NovG. Correspondingly, overexpression of novG under control of its own promoter 
stimulated novobiocin production even in a novE-defective strain. Vice versa, a novG 
defect strain could be complemented (at least partially) by overexpression of novE. 
These studies were carried out by heterologous expression of the modified cluster in 
the completely sequenced host S. coelicolor. The genome of S. coelicolor (Bentley et 
al., 2002) does not contain any orthologues of novE or novG, which may functionally 
replace the experimentally deleted genes within the novobiocin cluster. 
 
Taken together the results of these investigations prove that both novE and novG act 
as positive regulators of novobiocin biosynthesis, although the exact mechanism of 
their interplay was not clearified by these studies. Notably, NovE has been identified 
as a newly discovered tool to enhance novobiocin production. It remains to be shown 
whether the nine orthologues of novE deposited in the database, among them lmbU 
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from the lincomycin and rubC4 from the rubradirin biosynthetic gene cluster, can 
likewise be used to increase the production of the respective secondary metabolites. 
 
IV.2. Genetic organization and transcriptional regulation of the 
novobiocin biosynthetic gene cluster 
 
In order to investigate whether novE and novG act as transcriptional activators of 
novobiocin biosynthetic genes and to investigate the interplay of these two regulators, 
qRT-PCR experiments have been carried out.  
 
After the establishment of qRT-PCR for investigations on the novobiocin cluster, the 
following experiments provide the first direct proof that novE and novG act as 
transcriptional regulators of novobiocin biosynthesis. For novG, this result was 
expected, as its gene product shows 41 % identity on the amino acid level to strR, an 
established transcriptional regulator of streptomycin biosynthesis (Retzlaff & Distler, 
1995; Tomono et al., 2005). In contrast, novE has only few orthologues in other 
secondary metabolic gene clusters and sequence genomes, and no previous 
evidence existed on the function of these genes. 
 
qRT-PCR experiments, comparing transcription levels in strains containing either an 
intact or a novG-defective novobiocin cluster, showed that effective transcription from 
the novH promoter depended on the presence of novG (Fig. III.5e). At least the 
seven genes novHIJKLMN are apparently transcribed as a single operon (Fig. III.4e). 
In a mutant containing a terminator cassette (Ωaac) in the coding sequence of either 
novH, novO or novP, RT-PCR showed transcripts of novO, novP and novQ, 
respectively, suggesting the presence of promoters upstream of these genes. 
However, qRT-PCR with the ΩnovH mutant proved that transcription of novQ was 
much lower in this mutant than in a strain with the intact cluster, showing that the 
promoters upstream of novO, novP and novQ contributed only little to the overall 
transcription of novQ. The most plausible explanation of this observation is that the 
rate of transcription of novOPQ is primarily controlled by the novH promoter which 
initiates transcription of a large polycistronic mRNA. Since also novQRSTUVW 
apparently are part of a single operon (Fig. III.4h and i), it appears likely that all of the 
16 genes from novH to novW, which together direct all steps of novobiocin 
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biosynthesis from glucose-1-phosphate and 4-hydroxyphenylpyruvate or tyrosine (Fig. 
I.3), are transcribed predominantly in form of a single 18.000 nt transcript. Possibly, 
even the resistance gene gyrBR may be included in this transcript, extending it to 
20.000 nt. Transcripts of this rise are not unusual in secondary metabolic gene 
clusters, as the coding sequences of modular polyketide synthase or nonribosomal 
peptide synthase genes often span even larger DNA regions. However, other 
examples of a secondary metabolic gene clusters where 15 or 16 individual genes 
are transcribed onto a single mRNA have not been described yet. 
 
Whithin the suggested large operon starting with novH, RT-PCR had indicated the 
presence of internal promoters upstream of novO, novP and novQ. Internal 
promoters within operons have been described previously in Streptomyces, e.g. 
galP2, a low-level constitutive promoter internal to the galactose operon in 
Streptomyces lividans and Streptomyces coelicolor A3(2).  
 
A recent study  suggested that in Streptomyces coelicolor (in contrast to E. coli and 
Bacillus subtilis), expression levels of the individual genes of an operon decrease 
with increasing distance from the transcription start, and suggested that the 
frequently encountered internal promoters may ensure adequate transcription of the 
terminal genes of an operon (Laing et al., 2006). Under experimental conditions, 
however, transcription from the internal promoters upstream of novO, novP and novQ 
was low, and it cannot be decided whether they have any significant role in the 
transcription of the novobiocin biosynthetic genes.  
 
Sequence analysis did not show the characteristic sequence of NovG binding-site in 
the novOPQ-region, and EMSA assays did not show binding NovG (or NovE) in the 
intergenic region upstream of novO. This, and the low transcript levels for novQ in the 
ΩnovH strain suggest, that the weak internal promoters in the novOPQ region are not 
regulated by novG or novE, and may not be regulated at all.  
 
This study shows that effective transcription of novG depends on the presence of 
novE (Fig. III.5d). This suggests a cascade-like regulation mechanism of novE and 
novG, i.e. novE triggers transcription of novG, which in turn triggers transcription of 
the novobiocin biosynthetic genes. Consistant with this hypothesis, it was shown that 
novobiocin formation in a novE-defective mutant could be restored by an intact copy 
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of novG on a multicopy plasmid, while novobiocin formation in a novG-defective 
mutant remained low even after expression of novE from a multicopy plasmid. 
 
Transcription of the novobiocin resistance gene gyrBR may initially occur as part of 
the large transcript starting from novH, but later on obviously follows a different 
pattern (Fig. III.5i). Our results may be perfectly explained by the hypothesis of 
(Thiara & Cundliffe, 1989) that a promoter located upstream of gyrBR is regulated by 
the superhelical density of DNA, which in turn is influenced by the accumulation of 
the gyrase inhibitor novobiocin, acting on the constitutively expressed 
aminocoumarin-sensitive gyrBS subunit of gyrase. 
 
Therefore, the results of the study on the genetic organisation and transcriptional 
regulation of the novobiocin cluster can be summarized in the model depicted in Fig. 
IV. In this model, novE positively regulated transcription of novG. Since we could not 
demonstrate binding of the NovE protein to the DNA region upstream of novG (Fig. 
III.2b), the mechanism of regulation by novE is yet unknown. NovE may undergo a 
modification (e.g. phosphorylation) and bind to another, unknown protein before 
interacting with the novG promoter region, or it may release a repressor from this 
region, or trigger another event which ultimately induces transcription from the novG 
promoter. 
 
Expression of the novG-ortholog strR in the streptomycin cluster is triggered by the 
binding of AdpA to defined binding-sites located in the 406 bp intergenic region 
upstream of strR (Tomono et al., 2005). However, the consensus sequence for the 
AdpA binding-site is not found in the 105 bp intergenic region upstream of novG, and 
neither in the coding sequence of the preceding gene novF. Therefore, regulation of 
the novG expression appears to be different from that of strR expression in the 
streptomycin cluster. 
 
All experiments of this study were carried out in a heterologous producer strain S. 
coelicolor M512 (a derivative of S. coelicolor A3(2)) with the novobiocin gene cluster 
integrated into the ΦC31 attachment site of the chromosome. Exactly as described 
for the genuine producer strain (Kominek, 1972) novobiocin production in the CDM 
medium (see experimental) occured after the growth phase, suggesting that novE 
and novG expression may be regulated in a similar timely fashion as in the genuine 
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novobiocin producer strain. The exact mechanism for this regulation remains to be 
elucidated in both strains. 
 
Clearly, this study suggests that initiation of transcription from the novH promoter is 
the most important event for the regulation of novobiocin biosynthesis in the 
heterologous host. Transcription from this promoter is controlled by the DNA-binding 
protein NovG, which binds to a well-defined inverted repeat sequence in the 
intergenic region between novG and novH. (Fig. IV). This knowledge could be utilized 
to achieve an 8.4-fold overproduction of novobiocin by utilization of an optimized 
expression vector for novG. 
 
 
 
 
Fig. IV: Model of the genetic organization and transcriptional regulation of the novobiocin 
biosynthetic gene cluster. 
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IV.3. Regulation of novobiocin production by tetracycline-
controllable promoter 830 (tcp830) 
 
Antibiotic production is regulated by both, pathway-specific and global regulatory 
genes (Takano, 2006). Since the borders of the novobiocin biosynthetic gene cluster 
have been identified (Dangel et al., 2008; Eustáquio et al., 2005a) and the functions 
of most of the genes contained therein has been (Li & Heide, 2004), the presence of 
further pathway-specific regulators, in addition to novE and novG, may be excluded. 
Inactivation of both regulators, i.e. novE and novG, resulted in an almost loss of 
novobiocin production. 
 
Strong promoters were commonly used to overexpress single genes, since their use 
to express entire gene clusters is often limited by the fact that gene clusters consist 
of multiple transcripts. Recently, the replacement of pathway-specific regulatory 
genes and native promoter regions within a biosynthetic gene cluster with ermEp*, 
has been described as a strategy not only to uncouple secondary metabolite 
production from its natural regulation cascade, but moreover to result in enhanced 
antibiotic production, i.e. the replacement of the 3.4 kb regulatory region in the 
jadomycin biosynthetic gene cluster, including four regulatory genes and the 
promoter region PJ, by the constitutive promoter ermEp* resulted in increased 
jadomycin B production in Streptomyces venezuelae (Zheng et al., 2007).  
 
In addition to ermEp*, representing a constitutive promoter, several inducible 
promoters are available. Previous investigations confirmed the tetracycline 
controllable promoter 830 (tcp830) to reach induction factors of up to 270 (Rodriguez-
Garcia et al., 2005). In the present study tcp830 has been confirmed of being 
sufficient to transcribe an entire gene cluster of at least 18 kb, resulting in high 
antibiotic production. Notably, a recent study (Laing et al., 2006) suggested that in 
Streptomyces coelicolor (in contrast to E. coli and Bacillus subtilis), expression levels 
of the individual genes of an operon decreases with increasing distance from the 
transcription start. 
 
The finding that the replacement of the entire novEFG-region, including  the promoter 
region upstream of novH, by tcp830, i.e. in S.coelicolor M512 (nov-VD7), resulted in 
2-fold overproduction of novobiocin is in accordance with the result obtained in this 
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thesis that initiation of transcription from the novH promoter is the most important 
event for the regulation of novobiocin biosynthesis in the heterologous host. 
 
Moreover, the observed high novobiocin production in S. coelicolor M512 (nov-VD7) 
and S. coelicolor M512 (nov-VD9), both lacking the putative prephenate-
dehydrogenase novF, excludes an essential function for novF in novobiocin 
biosynthesis in the heterologous host. novF may be functionally replaced by 
SCO1761, encoding for a putative prephenate-dehydrogenase with 44% sequence 
homology on the amino acid level to novF. 
 
In conclusion, the control of novobiocin production by use of the inducible promoter 
tcp830 has been identified as a new tool to enhance antibiotic production. 
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